

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16

**Co-targeting myelin inhibitors and CSPGs enhances sensory axon regeneration
within, but not into, the spinal cord**

Jinbin Zhai, Hyukmin Kim, Seung Baek Han, Meredith Manire, Rachel Yoo, Shuhuan Pang,
George M. Smith and Young-Jin Son*

Shriners Hospitals Pediatric Research Center and Center for Neural Repair and Rehabilitation,
Lewis Katz School of Medicine, Temple University, Philadelphia, PA 19140

* Corresponding author: Young-Jin Son, PhD
Tel: (215) 926-9354
Email: yson@temple.edu

17 **ABSTRACT**

18 A major barrier to intraspinal regeneration after dorsal root (DR) injury is the DR entry zone
19 (DREZ), the CNS/PNS interface. DR axons stop regenerating at the DREZ, even if regenerative
20 capacity is increased by a conditioning lesion. This potent blockade has long been attributed to
21 myelin-associated inhibitors and CSPGs, but incomplete lesions and conflicting reports have
22 hampered conclusive agreement. Here we evaluated DR regeneration in adult mice, using novel
23 strategies to facilitate complete lesions and comprehensive analyses, selective tracing of proprio-
24 /mechanoreceptive axons with AAV2, and genetic or viral targeting of Nogo, MAG, OMgp,
25 CSPGs and GDNF. Simultaneously eliminating Nogo/MAG/OMgp elicited little intraspinal
26 penetration of DR axons, even with additional removal of CSPGs and a conditioning lesion.
27 Their absence, however, synergistically enhanced GDNF-elicited intraspinal regeneration. We
28 conclude that myelin inhibitors and CSPGs constrain intraspinal regrowth of DR axons, but that
29 they are not the primary mechanism(s) stopping axons at the DREZ.

30

31 **INTRODUCTION**

32 The dorsal root (DR) carries primary sensory axons that project centrally from dorsal root
33 ganglion (DRG) neurons to secondary neurons within the spinal cord and brainstem. DR injuries
34 commonly result from brachial plexus, lumbosacral plexus and cauda equina trauma, and may
35 cause permanent loss of sensation, uncoordinated movement and chronic pain (Carlstedt, 2008;
36 Kaiser et al., 2020). The devastating consequences are because DR axons stop regenerating at the
37 entrance of the spinal cord, the dorsal root entry zone (DREZ), and thus fail to restore
38 connections with secondary neurons. Animal studies have reported functional recovery of
39 nociception (Ramer et al., 2000; Cafferty et al., 2007; Liu et al., 2009; Lin et al., 2014;
40 Kelamangalath et al., 2015), and, less frequently, of proprioception and mechanoreception (e.g.,
41 Wang et al., 2008; Cheah et al., 2016), for which large-diameter, myelinated axons must
42 regenerate far longer distances after crossing the DREZ.

43

44 Both neuron-intrinsic and extrinsic inhibitors, which limit axon regrowth elsewhere in the
45 injured CNS (O'Shea et al., 2017; Griffin and Bradke, 2020), are widely thought to block
46 regeneration at the DREZ. Notably, however, unlike direct CNS injury, DR injury damages
47 axons peripherally in the PNS without causing an impassable glial scar. Nevertheless, DR axons

48 regenerating along the root quickly stop at the scar-free DREZ, even after a nerve conditioning
49 lesion (Chong et al., 1999; Zhang et al., 2007; Di Maio et al., 2011). This potent blockade is
50 surprising because a nerve conditioning lesion sufficiently enhances the growth potential of DRG
51 neurons to penetrate a glial scar after spinal cord injury (Neumann and Woolf, 1999; Kwon et al.,
52 2015). Why the scar-free DREZ is impenetrable even to conditioned axons remains unclear, but
53 myelin-associated inhibitors and extracellular matrix-associated chondroitin sulfate
54 proteoglycans (CSPGs) are conventionally considered responsible (Smith et al., 2012; Mar et al.,
55 2016). Consistent with this notion, soluble peptides blocking interactions between myelin
56 inhibitors and Nogo receptors are reported to dramatically enhance robust functional
57 regeneration of myelinated, but not non-myelinated, axons after DR crush (Harvey et al., 2009;
58 Peng et al., 2010). Similarly, blocking PTP σ , a CSPG receptor, is reported to produce functional
59 regeneration of myelinated DR axons into the spinal cord (Yao et al., 2019). Activating integrins
60 has been found to elicit long-distance, topographic and functional regeneration of both
61 myelinated and unmyelinated DR axons, presumably by counteracting myelin inhibitors, CSPGs
62 and tenascin-C (Tan et al., 2011; Cheah et al., 2016).

63
64 At least some of these observations have not been reproducible (Kelamangalath et al., 2015), and
65 conflicting studies have reported that removing CSPGs alone enables only minimal penetration
66 of DR axons through the DREZ (Steinmetz et al., 2005; Wu et al., 2016). CSPG removal,
67 however, when combined with conditioning lesions, neurotrophic factors or inflammation, has
68 significantly enhanced intraspinal regeneration of DR axons (Steinmetz et al., 2005; Wu et al.,
69 2016; Guo et al., 2019). These reports have supported a major inhibitory role of CSPGs by
70 suggesting that removing CSPGs alone only modestly increases regeneration presumably
71 because myelin inhibitors are sufficient to stop axons at the DREZ.

72
73 Despite the long-held view attributing the potent blockade to myelin inhibitors and CSPGs,
74 whether they indeed are primarily responsible for the regeneration failure at the DREZ has not
75 been determined. It is also unknown whether they are equally potent and act synergistically. Also
76 undetermined is whether their removal promotes regeneration of DR axons within the spinal cord
77 in addition to across the DREZ and how robustly unconditioned or conditioned DR axons
78 regenerate in the absence of both myelin inhibitors and CSPGs.

79
80 The present studies address these questions and attempt to determine the roles of myelin
81 inhibitors and CSPGs at the DREZ and within the spinal cord. We selectively traced regenerating
82 proprioceptive and mechanoreceptive axons and used a novel wholemount assay to ensure that
83 DR lesions were complete and the analysis comprehensive. We found that DR axons rarely
84 penetrate the DREZ, even after supplementary removal of CSPGs and addition of a conditioning
85 lesion, in triple knockout (tKO) mice lacking major myelin inhibitors-Nogo (A, B, C), MAG and
86 OMgp. Their absence, however, synergistically enhances intraspinal regeneration of DR axons
87 elicited by GDNF. Thus, myelin inhibitors and CSPGs are not crucial factors blocking sensory
88 axons at the DREZ, although they synergistically constrain regrowth of DR axons within the
89 spinal cord. These findings substantially advance current understanding of sensory axon
90 regeneration across the CNS/PNS border.

91

92 **RESULTS**

93 **Intraganglionic AAV2-GFP selectively labels proprioceptive and mechanoreceptive axons**

94 Conventional assessment of DR regeneration has relied heavily on immunolabeling of tissue
95 sections and consequently was subject to labeling artifacts and limited sensitivity. We initiated
96 the present study by identifying a viral tracer that intensely and reliably labels regenerating DR
97 axons. We tested various recombinant viral vectors carrying fluorescent reporters by
98 microinjecting them into cervical DRGs of uninjured adult mice. Of those we examined at 2
99 weeks post-injection, AAV2-GFP (self-complementary adeno-associated virus serotype 2-
100 enhanced green fluorescent protein) almost exclusively transduced neurons, revealing brightly
101 labeled cell bodies and axons (Figure 1A). After optimizing the virus titer, dosage and
102 microinjection technique, we were able to infect >70% neurons in most injections of DRGs
103 (Figure 1B). Infected neurons included the three broadly classified subtypes of DRG neurons:
104 large, neurofilament (NF)+ neurons, small- and medium sized IB4+ non-peptidergic neurons and
105 small CGRP+ peptidergic neurons (Figure 1C). Notably, a majority of the transduced, GFP-
106 expressing neurons were NF+ (Figure 1D). In contrast, IB4+ neurons rarely were GFP+ and
107 ~30% of GFP+ neurons were CGRP+ (Figure 1D), indicating that NF+ neurons were
108 disproportionately transduced by AAV2-GFP. Consistent with the preferential infection of NF+
109 neurons, brightly labeled, large-diameter axons projected into the deeper layers of the dorsal

110 horn (layer III-V) and into ventral horn, where large myelinated axons terminate (Figure 1E). In
111 contrast, superficial laminae of the dorsal horn, where small diameter unmyelinated axons
112 terminate (layer I, II), lacked GFP fluorescence (Figure 1E' and E''), showing that AAV-GFP
113 labels few if any IB4+ and CGRP+ axons. These findings demonstrate that AAV2-GFP
114 predominantly transduces NF+ neurons and selectively reveals their axons within the spinal cord.
115
116 NF+ neurons extend large-diameter myelinated axons that relay proprioception or
117 mechanoreception via second order neurons located deep in the spinal cord and in distant dorsal
118 column nuclei in the medulla (Niu et al., 2013). In contrast, IB4+ and CGRP+ neurons relay
119 nociception through small-diameter unmyelinated axons that innervate secondary neurons in the
120 superficial dorsal horn. Therefore, proprio-/mechanoreceptive axons require far more robust
121 long-distance regeneration than nociceptive axons for functional recovery. Moreover, myelinated
122 proprio-/mechanoreceptive axons regenerate more poorly than nonmyelinated nociceptive axons
123 (Tessler et al., 1988; Guseva and Chelyshev, 2006; Han et al., 2017). Therefore, AAV2-GFP
124 provides a unique opportunity to study selectively regeneration of proprio-/mechanoreceptive
125 axons whose regenerative capacity is particularly weak and needs robust augmentation.

126

127 **Strategies for complete lesions and comprehensive evaluation of DR regeneration**

128 Regeneration studies in animals suffer from conflicting and non-reproducible results, in part due
129 to incomplete lesions which lead to mistakenly interpreting spared axons as regenerating axons
130 (Steward et al., 2003; Steward et al., 2012). Completely crushing a DR is particularly demanding
131 because DRs are tightly attached to spinal cord surfaces in flat, transparent layers (Han et al.,
132 2012; Son, 2015). Various surgical methods have been applied to facilitate complete lesions,
133 such as repetitive and bidirectional crushing of a root (Steinmetz et al., 2005; Wu et al., 2016).
134 However, there have been no assays that would confirm that a surgery was successful.

135

136 We used two strategies to avoid spared axons. In one, we first crushed DRs and then micro-
137 injected AAV2-GFP into DRGs (Figure 2A). This strategy transduces only axons proximal to the
138 lesion, leading to labeling of regenerating, but not degenerating, distal stump axons. This is
139 important because distal axons are very slowly removed in the CNS (Vargas and Barres, 2007),
140 and thus can be mistakenly identified as regenerating axons in a conventional immunostaining

141 analysis of transverse sections. In the second strategy, after euthanizing a mouse typically at 2
142 weeks post injury (wpi), we harvested spinal cords with attached DRs and DRGs, examined them
143 first in wholemounds and excluded those with poor viral infections. We then carefully examined
144 the properly labeled wholemounds and confirmed that lesions were complete (e.g., Figure 2B).
145 We excluded those containing spared axons with the following characteristics: present in groups
146 of only a few, relatively straight and extremely lengthy axon trajectories that extend along the
147 entire length of the spinal cord and terminate with no discernable axon endings (e.g., Figure 2C;
148 Han et al., 2012). A highly experienced surgeon performed all the root crushes. Nevertheless,
149 incomplete lesions occurred in ~20% of the animals, typically because axons had been spared in
150 the outermost dorsal rootlets (Figure 2C).

151
152 The wholemounds also enabled us to examine an unprecedented number of regenerating proprio-
153 /mechanoreceptive axons from multiple injured roots. After a complete root crush in a wildtype
154 (WT) mouse, hundreds of GFP+ axons all terminated at similar locations along the length of the
155 dorsolateral spinal cord (Figure 2B). Consistent with earlier studies of tissue sections (Golding et
156 al., 1999; Di Maio et al., 2011), wholemounds revealed that GFP+ axons crossed the
157 astrocyte:PNS border and terminated mostly within ~200 μ m of the border, forming a narrow
158 front of axon tips (Figure 2D). Following wholemound assessment, we prepared serial transverse
159 sections and evaluated regeneration of DR axons, across the DREZ and within the spinal cord. In
160 WT mice, axons frequently grew dorsally along the growth-permissive pia matter (Figure 2E;
161 arrowheads). We occasionally observed axons located subdurally several hundred microns past
162 the astrocyte:PNS border (Figure 2E; arrow). Most axons, however, were located within ~100 μ m
163 of the border and only a few axons reached ~200 μ m (Figure 2F). In the present comparative
164 analyses, we considered axons that grew farther than 100 μ m as having penetrated the DREZ.
165 When astrocytes could not be co-immunostained, the border was approximated based on the
166 greater abundance of cell nuclei in the PNS than CNS (Figure 2E).

167 168 **Genetic deletion of Nogo, MAG and OMgp elicits no regeneration across the DREZ**

169 We first investigated the effects of simultaneous deletion of myelin-associated inhibitors by
170 examining global tKO mice lacking Nogo isoforms (A, B, C), MAG and OMgp. These mice
171 were initially raised on a mixed background, extensively characterized and used to study spinal

172 cord regeneration (Lee et al., 2010). Our examination of these non-congenic tKO mutants
173 revealed no enhanced regeneration of DR axons across the DREZ (data not shown). To
174 overcome possible complications due to genetic background (Montagutelli, 2000; Tedeschi et al.,
175 2017), we subsequently obtained Nogo/OMgp double KO and MAG KO mice raised on a
176 C57BL/6 background and bred them to generate congenic Nogo/MAG/OMgp tKO mice, which
177 we confirmed by tail genotyping (Figure 3A). Congenic tKO mice were viable and fertile, with
178 no gross abnormalities. They were intercrossed to generate additional 2-3 month- old tKO mice;
179 age matched C57BL/6 mice were used as controls.

180

181 To examine DR regeneration, we unilaterally crushed L4 and L5 DRs ~3-5 mm from the DREZ
182 and then microinjected high-titer AAV2-GFP into the ipsilateral L4 and L5 DRGs (Figure 3B).
183 In this crush injury model, proximal axons of large, NF+ neurons are capable of regenerating
184 across the injury site and growing along the root at ~1.5 mm/day until they are rapidly
185 immobilized at the DREZ, ~4 days post injury (Di Maio et al., 2011). We examined WT and
186 tKO at 2 wpi, which provides axons sufficient time to penetrate the DREZ if they are competent
187 to do so. Wholemout examination of Nogo/MAG/OMgp tKO mice revealed many brightly
188 labeled axons that extended along the L4 and L5 roots (Figure 3C), as they did also in WT mice
189 (Figure 2B). In both tKO and WT mice, however, most GFP+ axons terminated at similar
190 longitudinal locations near the astrocyte:PNS border. Some axons extended substantially longer
191 processes dorsally toward the spinal cord midline (Figure 3C; arrow). However, similar axons
192 were also frequent in WT, and their incidence and length were not noticeably different in tKO
193 and WT mice. We next examined serial transverse sections of L4 and L5 spinal cords prepared
194 from tKO mice. No sections revealed GFP+ axons that crossed the DREZ and grew deep into the
195 spinal cord. Most axons stopped at the DREZ, within ~100µm of the astrocytic border, as in WT
196 (Figure 3D, 3E). Axons that extended longer distances grew along the growth-permissive pia
197 matter (Figure 3D; arrowheads), as in WT (Figure 2E). Thus, genetic elimination of three major
198 myelin inhibitors did not enable GFP+ axons to cross the DREZ. These results suggest that
199 inhibiting myelin associated growth inhibitors is insufficient for proprio-/mechanoreceptive
200 axons to penetrate the DREZ.

201

202 **Supplementary CSPG removal enables minimal regeneration across the DREZ in tKO**
203 **mice**

204 The limited regeneration across the DREZ in Nogo/MAG/OMgp tKO could be due to redundant
205 inhibition by CSPGs that by themselves are capable of arresting axons at the DREZ. Conversely,
206 CSPG removal might induce only minimal regeneration (Steinmetz et al., 2005; Wu et al., 2016)
207 due to redundant and potent inhibition by myelin inhibitors. To test this possibility, we
208 attenuated CSPGs in Nogo/MAG/OMgp tKO using lentivirus encoding Chondroitinase ABC
209 (LV-chABC). ChABC promotes axon regrowth by digesting growth-inhibitory
210 glycosaminoglycan (GAG) chains on CSPGs (Muir et al., 2019). We unilaterally crushed L4 and
211 L5 DRs of Nogo/MAG/OMgp tKO, microinjected AAV2-GFP into the L4 and L5 DRGs, and
212 injected high-titer LV-ChABC into the ipsilateral dorsal horn at multiple locations rostrocaudally
213 along the L4-L5 DREZ (Figure 4A). Two weeks after injury, wholemounds of ChABC-expressed
214 tKO mice appeared similar to those of WT mice: most GFP⁺ axons terminated near the
215 astrocytic border (Figure 4B). We used CS56 antibody immunostaining to confirm that LV-
216 ChABC effectively removed the inhibitory sulfated GAG chains on CSPGs (Figure 4C).
217 Consistent with previous observations (Han et al., 2017), CSPG degradation was restricted to the
218 dorsal horn on the injected side of the spinal cord (Figure 4C; asterisks). Notably, CSPGs were
219 rapidly and markedly upregulated in Schwann cells after DR crush, resulting in far brighter CS-
220 56 immunoreactivity in the PNS than in the CNS (data not shown). We observed considerable
221 CS-56 immunoreactivity associated with Schwann cells near the DREZ in ChABC-expressed
222 tKO mice (Figure 4C'; arrowhead). However, the intensity of immunoreactivity was markedly
223 reduced compared to that in non-treated tKO mice, further suggesting that CSPGs at the DREZ
224 were markedly attenuated by LV-ChABC.

225
226 Most of the serial transverse sections of L4 and L5 DREZ also showed DR axons arrested at the
227 DREZ and were virtually indistinguishable from those of WT mice. Some sections exhibited a
228 few GFP⁺ axons located slightly deeper in the dorsal funiculus; such axons were not observed in
229 WT or tKO (Figure 4C'; arrows). These axons were within 200 μ m of the astrocytic border and
230 constituted only ~10% of GFP⁺ axons (Figure 4D), however, suggesting that additional
231 attenuation of CSPGs in Nogo/MAG/OMgp tKO only modestly promoted regeneration across
232 the DREZ.

233

234 **Chronic regeneration failure at the DREZ despite absence of Nogo/MAG/OMgp and**
235 **CSPGs**

236 Concurrent ablation of myelin inhibitors and CSPGs only minimally enhanced regeneration, as
237 assessed at 2 wpi, enabling only ~10% GFP+ axons to reach intraspinally ~100 μ m past the
238 DREZ. Additional axons may continue to penetrate the DREZ and grow within the spinal cord
239 lacking myelin inhibitors and CSPGs. To investigate this possibility and the chronic effects of
240 targeting myelin inhibitors and CSPGs, we next examined WT, Nogo/MAG/OMgp tKO and
241 ChABC-expressed tKO mice at 4 wpi (Figure 5A). Consistent with earlier studies that
242 demonstrated rapid and persistent immobilization of DR axons at the DREZ (Golding et al.,
243 1996; Di Maio et al., 2011), WT mice exhibited no enhanced regeneration across the DREZ at 4
244 wpi, as examined in wholemounds (Figure 5B) or in transverse sections (Figure 5C). There was,
245 however, a statistically insignificant increase in DR axons at the DREZ (Figure 5D).

246

247 Similarly, in Nogo/MAG/OMgp tKO at 4 wpi (Figure 5E, 5F, 5G), we found no qualitative or
248 quantitative evidence that two additional weeks after injury enabled more axons to penetrate the
249 DREZ. This observation suggests that DR axons were chronically immobilized as they entered
250 the DREZ despite the absence of myelin inhibitors.

251

252 Likewise, ChABC-expressed Nogo/MAG/OMgp tKO mice exhibited little or no enhanced
253 regeneration at 4 wpi, as examined in wholemounds (Figure 5H) and transverse sections (Figure
254 5I). We observed no increase in GFP+ axons that crossed the DREZ, indicating that no
255 additional axons penetrated the DREZ and that those axons intraspinally located at 2 wpi (~10%
256 GFP+ axons) did not extend further within the spinal cord lacking CSPGs. We observed
257 significantly more axons at the DREZ in ChABC-expressed Nogo/MAG/OMgp tKO mice at 4
258 wpi than at 2 wpi (Figure 5J) or than in WT or Nogo/MAG/OMgp tKO mice at 4 wpi (Figure
259 5K). Notably, however, these GFP+ axons remained at the DREZ, indicating that prolonged
260 attenuation of CSPGs did not enable them to penetrate the DREZ lacking Nogo, MAG and
261 OMgp.

262

263 We also examined regeneration of CGRP⁺ nociceptive axons, which are not discernably labeled
264 by AAV2-GFP. As anticipated, it was often not possible, as noted in WT mice at 2 wpi, to
265 evaluate intraspinal regeneration on sections due to punctate residual CGRP immunoreactivity
266 associated with superficial laminae of the ipsilateral dorsal horn, particularly in Lissauer's tract
267 (Figure 2E: asterisks). Dorsal funiculus above the dorsal horn, however, largely lacked CGRP⁺
268 immunoreactivity, indicating little if any penetration of CGRP⁺ axons through the DREZ at 2
269 wpi in WT mice (Figure 2E). Similarly, dorsal funiculus lacked CGRP immunoreactivity at 4
270 wpi in WT (Figure 5C), Nogo/MAG/OMgp tKO (Figure 5F) and ChABC-expressed
271 Nogo/MAG/OMgp tKO mice (Figure 5I). CGRP immunoreactivity in superficial laminae of
272 these mice at 4 wpi appeared similar to that in WT mice at 2 wpi. Moreover, it was not directly
273 connected to CGRP⁺ axons at the DREZ on any sections, indicating that no axons reached
274 superficial laminae directly through the DREZ. Thus, CGRP⁺ axons also stop at the DREZ even
275 with concurrent prolonged absence of myelin inhibitors and CSPGs. Collectively, these results
276 demonstrate that both myelinated and unmyelinated DR axons stop at the DREZ and continue to
277 be immobilized, even if myelin inhibitors and CSPGs are simultaneously removed. Therefore,
278 the minimal regeneration observed in earlier studies targeting CSPGs was not due to redundant
279 inhibition by myelin associated inhibitors. Instead, these findings suggest that neither myelin
280 inhibitors nor CSPGs are critical in preventing regeneration of DR axons at the DREZ.

281

282 **DR axons fail to penetrate the DREZ in Nogo/MAG/OMgp tKO even after a conditioning** 283 **lesion**

284 Although genetic deletion of myelin inhibitors alone does not permit DR axons to grow through
285 the DREZ, it may enable conditioned axons with enhanced growth capacity to do so. To test this
286 possibility, we performed a nerve conditioning lesion by crushing the sciatic nerve 10 days
287 before crushing the L4 and L5 roots (Figure 6A). At 2 wpi, wholemounts of GFP⁺ axons in
288 conditioned Nogo/MAG/OMgp tKO mice did not show noticeably enhanced penetration of the
289 DREZ (Figure 6B). Accordingly, serial transverse sections occasionally exhibited a few axons
290 that reached dorsolateral grey matter (Figure 6C: arrows), but most GFP⁺ axons failed to
291 penetrate the DREZ (Figure 6C, 6D). Dorsal funiculus lacked CGRP immunoreactivity,
292 suggesting that conditioned CGRP⁺ axons also failed to penetrate the DREZ. Compared to WT
293 and tKO mice, conditioned tKO mice exhibited significantly more axons at the DREZ,

294 presumably reflecting enhanced regeneration in the peripheral portion of the DR (Di Maio et al.,
295 2011). We rarely observed axons extended more than $>200\mu\text{m}$ from the astrocytic border in
296 conditioned tKO mice, as in WT and non-conditioned tKO mice (Figure 6D). Therefore, removal
297 of myelin associated inhibitors does not enable even conditioned axons to regenerate beyond the
298 DREZ.

299

300 **Supplementary CSPG removal does not enhance intraspinal penetration in conditioned** 301 **tKO**

302 We next asked whether additional attenuation of CSPGs in Nogo/MAG/OMgp tKO mice would
303 enable robust penetration of conditioned axons through the DREZ. To test this possibility, we
304 injected LV-ChABC rostrocaudally in dorsal horns along the L4-L5 DREZ in
305 Nogo/MAG/OMgp tKO mice which received a nerve conditioning lesion 10 days before
306 crushing L4 and L5 roots (Figure 7A). Surprisingly, at 2 wpi, despite the concurrent degradation
307 of CSPGs, conditioned axons of Nogo/MAG/OMgp tKO mice largely remained near the
308 astrocytic border in wholemounts (Figure 7B). CS-56 antibody immunostaining confirmed
309 effective removal of CSPGs in dorsal horns (Figure 7C). Serial transverse sections occasionally
310 revealed GFP+ axons that reached dorsolateral grey matter (Figure 7D; arrows), but most axons
311 remained at the DREZ within $\sim 100\mu\text{m}$ of the border (Figure 7E). Similarly, we observed no
312 noticeably enhanced regeneration of CGRP+ axons in conditioned/ChABC-expressed
313 Nogo/MAG/OMgp tKO (Figure 7D). These results demonstrate that additional removal of
314 CSPGs did not enable significantly more GFP+ axons to penetrate the DREZ in conditioned tKO
315 mice. In sum, CSPG degradation and/or a conditioning lesion increases the number of axons at
316 the DREZ in Nogo/MAG/OMgp tKO mutants, but most of these axons fail to cross the DREZ
317 (Figure 7F). CSPG removal improves penetration of conditioned or unconditioned axons in tKO
318 mutant, but the effect is modest, enabling only $\sim 10\%$ axons to extend $\sim 100\mu\text{m}$ past the DREZ
319 (Figure 7F). These results collectively suggest that myelin inhibitors and CSPGs are not the
320 primary factors that arrest even conditioned DR axons at the DREZ.

321

322 **Nogo/MAG/OMgp removal enhances GDNF-induced intraspinal growth of DR axons**

323 Our findings that even conditioned DR axons penetrate only modestly through the DREZ in
324 ChABC-expressed tKO raise the possibility that myelin inhibitors and CSPGs are not

325 significantly inhibitory to DR axons. Alternatively, they may hinder regeneration within the
326 spinal cord, although their inhibition is not sufficient to block axons at the DREZ. To test this
327 possibility, we applied a treatment that enabled axons to penetrate the DREZ and then examined
328 if their intraspinal regeneration was altered in Nogo/MAG/OMgp tKO mice with or without
329 additional attenuation of CSPGs. Intraspinally expression of neurotrophic factors elevates
330 regenerative capacity and chemotropically attracts DR axons, enabling them to cross the DREZ
331 (Ramer et al., 2000; Iwakawa et al., 2001; Kelamangalath et al., 2015). When expressed virally
332 within the spinal cord, GDNF promoted penetration of large-diameter DR axons through the
333 DREZ and further into the spinal cord (Kelamangalath et al., 2015; Han et al., 2017).

334

335 We microinjected lentivirus expressing GDNF (LV-GDNF), extensively used in earlier studies
336 (Deng et al., 2013; Zhang et al., 2013; Kelamangalath et al., 2015; Han et al., 2017), into the
337 dorsal horn rostrocaudally along the L4-L5 DREZ at the time of DR crush in WT (Figure 8A) or
338 Nogo/MAG/OMgp tKO mice (Figure 8E). At 2 wpi, wholemounts of GDNF-expressed WT mice
339 did not show markedly enhanced regeneration into the spinal cord (Figure 8B). Serial sections,
340 however, frequently revealed GFP⁺ axons that crossed the DREZ and extended further into the
341 dorsal funiculus and grey matter (Figure 8C). Quantification indicated that ~50% of GFP⁺ axons
342 penetrated the DREZ and extended up to ~300 μ m from the astrocytic border (Figure 8D).
343 Consistent with an earlier study (Iwakawa et al., 2001), we also observed numerous CGRP⁺
344 axons in the dorsal funiculus, indicating regeneration of nociceptive axons across the DREZ.

345

346 Compared to GDNF-expressed WT mice, wholemounts of GDNF-expressed Nogo/MAG/OMgp
347 tKO mice frequently revealed areas of the DREZ that exhibited conspicuously intense GFP
348 fluorescence, likely due to densely accumulated subdural GFP⁺ axons (Figure 8F; arrows).
349 Indeed, serial sections often displayed abundant GFP⁺ axons at the DREZ and within the spinal
350 cord, indicating markedly enhanced intraspinal regeneration in tKO mutants (Figure 8G). We
351 also observed bright CGRP⁺ immunoreactivity in deep dorsal laminae which are usually devoid
352 of residual CGRP⁺ staining, presumably indicating enhanced regeneration of nociceptive axons
353 (Figure 8G; asterisk). The extent of intraspinal regeneration markedly exceeded that observed in
354 GDNF-expressed WT mice, nearly tripling the number of GFP⁺ axons counted at 200 μ m
355 centrally from the border (Figure 8H). Notably, many more GFP⁺ axons were present at the

356 DREZ and within the spinal cord than peripherally along the root (Figure 8H). These results,
357 together with the observation of GFP+ axons densely accumulated at the DREZ in wholemounts,
358 suggest that genetic deletion of Nogo/MAG/OMgp may have enhanced intraspinal regeneration
359 of DR axons largely by facilitating formation of additional axon branches (Figure 8H).
360 Collectively, these findings indicate that myelin inhibitors are indeed inhibitory to DR axons and
361 can substantially restrict their regeneration within the spinal cord. Importantly, however, genetic
362 deletion of myelin inhibitors does not by itself induce intraspinal regeneration but promotes
363 intraspinal regrowth of DR axons that has been elicited by a combinatory treatment.

364

365 **CSPG removal further enhances GDNF-elicited intraspinal regeneration in tKO**

366 Lastly, we investigated the synergistic effect of CSPG degradation on GDNF-elicited
367 regeneration in Nogo/MAG/OMgp tKO mutants to determine if CSPGs also restrict regrowth of
368 DR axons. We micro-injected LV-GDNF and LV-ChABC into dorsal horns and AAV2-GFP into
369 DRGs at the time of L4/L5 root crush (Figure 9A). At 2 wpi, wholemounts of GDNF/ChABC-
370 expressed tKO mice revealed broader areas of the DREZ and the CNS with intense GFP
371 fluorescence than in GDNF-expressed tKO mice (Figure 9B; arrows). Moreover, many GFP+
372 axons extended rostrocaudally close to the midline (Figure 9B; arrowheads), further evidence of
373 enhanced intraspinal penetration and regeneration. Accordingly, transverse sections frequently
374 showed GFP+ axons densely filling a broader and deeper area of the dorsal horn (Figure 9C,
375 9D). CGRP immunoreactivity on some sections was conspicuously bright, dense and notably
376 restricted to the superficial laminae, similar to CGRP immunoreactivity on the contralateral
377 uninjured side (Figure 9D). Compared to GDNF-expressed tKO, GDNF/ChABC-expressed tKO
378 mice showed significantly more GFP+ axons in deeper portions of the dorsal horn (Figure 9E).
379 These results show that additional removal of CSPGs synergistically enhanced intraspinal
380 regeneration elicited by GDNF in Nogo/MAG/OMgp tKO mice. Therefore, CSPGs, like myelin
381 inhibitors, restricts intraspinal regrowth of DR axons although it does not constrain them at the
382 DREZ.

383

384 **DISCUSSION**

385 Using novel multifaceted strategies, we compared DR regeneration in WT, Nogo/MAG/OMgp
386 tKO, ChABC-expressed tKO, GDNF-expressed tKO and GDNF/ChABC-expressed tKO mice,

387 either with or without a conditioning lesion. Co-eliminating myelin inhibitors and CSPGs
388 elicited only minimal intraspinal penetration, even after an additional conditioning lesion. Their
389 absence, however, synergistically enhanced GDNF-elicited intraspinal axon growth. These
390 findings suggest that a mechanism independent of myelin inhibitors and CSPGs vigorously
391 blocks axons at the DREZ, and that this barrier can be overcome by elevating neuronal growth
392 capacity above that achieved by a conditioning lesion. They also suggest that therapeutically
393 targeting myelin inhibitors and CSPGs alone can enhance, but will not induce, intraspinal
394 regeneration of primary sensory axons.

395
396 Various AAV vectors, including AAV2, demonstrate neuronal tropism (Mason et al., 2010;
397 Fischer et al., 2011). Several AAV serotypes exhibit differential tropism for specific
398 subpopulations of DRG neurons: AAV6 preferentially transduces small-sized neurons; AAV5, 8,
399 and 9, large neurons (Jacques et al., 2012; Yu et al., 2013; Wu et al., 2016; Kubota et al., 2019).
400 We found that AAV2 preferentially transduces NF+ neurons. Approximately 80% of GFP+
401 neurons were NF+, although only ~50% of lumbar DRG neurons are NF+ in mice (Li et al.,
402 2016). IB4+ neurons constituted only ~5% of GFP+ neurons whilst CGRP+ neurons accounted
403 for ~30%. Because ~30% of CGRP+ neurons also express NF200 (Li et al., 2016), our results are
404 likely an overestimation of CGRP+ neurons projecting nociceptive axons. GFP expression in
405 superficial dorsal laminae (I-III), where nociceptive afferents terminate, was almost undetectable
406 (Figure 1E). It appears, therefore, that the predominant transduction of NF+ neurons and minimal
407 expression of GFP in CGRP+ axons make AAV2-GFP a useful tracer of proprioceptive and
408 mechanoreceptive axons.

409
410 Axon sparing has hampered consistent and conclusive studies with the widely used DR crush
411 model (Smith et al., 2012). We found that complete crushing is difficult even in fluorescent mice
412 whose axons are well visualized. Furthermore, improperly crushed axons often recover
413 connectivity with distal axons (Di Maio et al., 2011; Han et al., 2012). Here we studied L4-L5
414 roots because in our experience DR crush is more likely to spare cervical than lumbar roots. In
415 addition, we used wholemount preparations to detect spared axons, which is possible because
416 AAV2-GFP brightly labels numerous axons. Importantly, however, wholemount assessment

417 does not guarantee complete lesions because viral transduction does not label all axons and
418 spared axons that are deeply located may be overlooked.

419

420 Wholemounds also permitted simultaneous assessment of many axons in multiple roots.

421 Markedly enhanced regeneration appeared as areas with unusually bright, dense GFP
422 fluorescence. Rostrally extending bundles of GFP+ axons were also observed when intraspinal
423 penetration exceeded 50%. These features require many intraspinally regenerating axons and
424 therefore provide convincing evidence of robustly enhanced intraspinal penetration.

425 Accordingly, wholemount assay is particularly useful for studies such as the present one, which
426 uses a relatively small number of animals. We excluded mice for various reasons, including
427 incomplete lesions and poor axon labeling, and used 3-8 mice per cohort to compare a total of 10
428 different animal groups. Nevertheless, no tKO, ChABC-expressed tKO, or conditioned/ChABC-
429 expressed tKO mice exhibited either fluorescent areas of densely populated axons or rostral axon
430 bundles. In contrast, these were consistent findings in all the wholemounts of GDNF-expressed
431 tKO and GDNF/ChABC-expressed tKO mice. Uniform absence or presence of these major
432 features in wholemounts is therefore useful to determine if a specific factor serves as a major
433 inhibitor or promoter of DR regeneration across the DREZ.

434

435 Wholemounds showed no such features and transverse sections revealed minimal intraspinal
436 penetration up to 4 wpi in Nogo/MAG/OMgp tKO with or without additional CSPG degradation.
437 More surprisingly, there was little enhancement even with conditioning lesions of ChABC-
438 expressed Nogo/MAG/OMgp tKO mice. Minimal enhancement was unlikely due to insufficient
439 removal of Nogo/MAG/OMgp or CSPGs. Most notably, GDNF robustly enhanced regeneration
440 in Nogo/MAG/OMgp tKO and produced even more regeneration in ChABC-expressed tKO
441 mice. These observations, together with earlier studies that demonstrated efficacy of the
442 Nogo/MAG/OMgp tKO and LV-ChABC (Curinga et al., 2007; Lee et al., 2010; Jin et al., 2011;
443 Han et al., 2017), indicate that penetration was not limited because of insufficient elimination of
444 Nogo, MAG, OMgp, CSPGs and/or undigested CSPG carbohydrate stubs (Lemons et al., 2003).
445 Our findings are consistent with earlier observations that degrading CSPGs alone (Steinmetz et
446 al., 2005; Wu et al., 2016), or in combination with conditioning lesions (Quaglia et al., 2008)
447 elicits minimal intraspinal penetration. Importantly, they demonstrate for the first time that the

448 minimal penetration elicited by the absence of CSPGs was unlikely due to synergistic restraint
449 by myelin inhibitors.

450

451 Co-eliminating myelin inhibitors and CSPGs was insufficient to achieve DR regeneration into
452 the spinal cord, even when combined with a conditioning lesion. These results contrast with the
453 robust, long-distance functional regeneration of myelinated DR axons reported in earlier studies
454 that targeted Nogo receptor or CSPG/CSPG receptors, with or without a conditioning lesion
455 (Harvey et al., 2009; Peng et al., 2010; Cheah et al., 2016; Yao et al., 2019). Blocking inhibitors
456 in adulthood may be more effective than eliminating them during development due to
457 compensatory upregulation of other inhibitors (El-Brolosy and Stainier, 2017). It is noteworthy,
458 however, that we removed CSPGs in adult tKO mice. Another possible explanation for the
459 discrepancy is a species difference between mice and rats (Lee and Lee, 2013), but results have
460 also conflicted in the same species. Additional myelin-associated inhibitors and ligands of Nogo
461 and CSPG receptors have been identified (Zhang et al., 2009b; Dickendesher et al., 2012;
462 Thiede-Stan and Schwab, 2015; Ohtake et al., 2018). However, CSPGs are the major additional
463 ligands that bind to the Nogo receptor (Dickendesher et al., 2012), yet co-eliminating CSPGs and
464 myelin inhibitors elicited little penetration. An alternative explanation is that these studies
465 included incomplete lesions of varying extent, which were followed by acute or gradual
466 functional recovery that did not require actual regeneration or relied on sprouting of spared axon
467 terminals (Cafferty et al., 2008). We failed to find convincing evidence, in these reports, of axons
468 penetrating the DREZ and regenerating for long distances, which would be necessary to support
469 either course of functional regeneration.

470

471 Targeting Nogo, CSPGs or their receptors in rodent models of spinal cord injury promotes little
472 regeneration of myelinated axons, such as corticospinal tract (Fink et al., 2015; Lang et al., 2015;
473 Ito et al., 2018). However, their removal can significantly enhance the growth promotion of a
474 combinatorial treatment (Wang et al., 2012; DePaul et al., 2017; Wu et al., 2017). Consistent with
475 these observations, we found that although eliminating myelin inhibitors alone did not induce
476 intraspinal penetration, it markedly enhanced GDNF-elicited intraspinal axon growth. This
477 intraspinal growth was further enhanced by concomitant removal of CSPGs, suggesting that both
478 myelin inhibitors and CSPGs synergistically inhibit regrowth of DR axons within the spinal cord.

479 Notably, we also observed a significantly increased number of axons at the DREZ in GDNF-
480 expressed tKO and in ChABC-expressed tKO mice. We infer, therefore, that myelin inhibitors
481 and CSPGs also constrain regeneration at the DREZ, but their absence is insufficient to enable
482 axons to cross the DREZ.

483
484 Myelin inhibitors and CSPGs are thought to stop axons at the DREZ by collapsing or trapping
485 growth cones and inducing dystrophic endings (Li et al., 1996; Golding et al., 1999; Ramer et al.,
486 2001; Tom et al., 2004; Smith et al., 2012). Our results revise this long-held view by suggesting
487 the presence of inhibitory mechanism(s) of greater potency that arrest even conditioned axons
488 and act independently of myelin inhibitors and CSPGs. One such inhibitory mechanism may be
489 the expression of additional repellent cues that are upregulated at the axotomized DREZ
490 (Andrews et al., 2009; Lindholm et al., 2017). Another possibility, which we favor, is that most
491 axons are stabilized at the DREZ by forming aberrant synapses rather than dystrophic endings
492 (Carlstedt, 1985; Liuzzi and Lasek, 1987; Stensaas et al., 1987; Di Maio et al., 2011; Son, 2015).
493 We could not confirm this possibility in the present study because of the experimental challenges
494 of differentiating dystrophic from synaptic endings, and in blocking aberrant synapse formation.
495 However, we have obtained additional evidence for a synapse-based inhibitory mechanism that
496 supports this notion (Kim et al., in preparation). Other possible, although less likely, mechanisms
497 include lack of a growth-permissive/promoting substrate (Li et al., 2004; Han et al., 2017;
498 Collins et al., 2019) and/or inadequate intrinsic growth ability of DRG neurons (Steinmetz et al.,
499 2005; Nichols and Smith, 2020).

500
501 Conditioning lesioned DRG neurons have been extensively used for epigenetic, transcriptomic
502 and proteomic studies of peripheral and central regeneration (Blesch et al., 2012; Li et al., 2015;
503 Palmisano et al., 2019). We found that GDNF, but not a conditioning lesion, enabled intraspinal
504 penetration in ChABC-expressed tKO mice. Therefore, a conditioning lesion does not
505 sufficiently elevate regenerative capacity to overcome the potent myelin/CSPG-independent
506 inhibitory mechanism(s). Although our results highlight the importance of sufficiently elevating
507 regenerative potential, GDNF enhanced penetration of less than 50% DR axons. Moreover, the
508 intraspinal regeneration it elicited in the absence of myelin inhibitors and CSPGs was apparently
509 enhanced but did not appear sufficiently robust to power the long-distance regeneration required

510 for proprio-/mechanoreceptive axons. The DR regeneration induced by several other
 511 neurotrophic factors, cytokines and downstream effectors has been generally weaker than that
 512 elicited by GDNF in ChABC-expressed tKO mice (O'Donovan et al., 2014; Liu et al., 2016; Wu
 513 et al., 2016). Learning how to maximize the regenerative potential must be as important as
 514 understanding the myelin/CSPG-independent mechanism that powerfully halts axons at the
 515 DREZ, and perhaps also within the damaged spinal cord.

516

517 MATERIALS AND METHODS

518

Reagent type (species) or resource	Designation	Source or Reference	Identifiers	Additional Information
Strain, strain background (<i>Mus musculus</i>)	Nogo/OMgp double knockout	Dr. Binhai Zheng (UCSD)		Lee et al., 2010
Strain, strain background (<i>Mus musculus</i>)	MAG knockout	Dr. Jae K. Lee (U.Miami)	Stock #: 006865; RRID:IMSR JAX:006865	
Strain, strain background (<i>Mus</i>	C57BL/6J	The Jackson Laboratory	Stock #: 000664; RRID:IMSR JAX:000664	

<i>musculus</i>)				
Reagent	Vectashield	Vector Laboratories, Burlingame	H-100 RRID:AB2336789	
Viral reagent	scAAV2-eGFP	Dr. George M. Smith (Temple University)		Liu et al., 2014
Viral reagent	LV-chABC	Dr. George M. Smith (Temple University)		Curinga et al., 2007
Viral reagent	LV-GDNF	Dr. George M. Smith (Temple University)		Zhang et al., 2013
Antibody	anti-NF200 (rabbit polyclonal)	Sigma	#N4142 RRID:AB477272	IHC 1:500
Antibody	anti-IBA-biotin conjugate	Sigma	#L2140 RRID:AB2313663	IHC 1:200
Antibody	anti-CGRP (rabbit polyclonal)	Peninsula Labs	#T4032 RRID:AB2307330	IHC 1:2,000
Antibody	anti-GFP monoclonal	Avés Labs Inc.	#GFP-1020 RRID:AB10000240	IHC 1:500

Antibody	anti-GFAP (rabbit polyclonal)	Agilent	#N1506 RRID:AB10013482	IHC 1:500
Antibody	Alexa Fluor 647-goat anti-rabbit IgG secondary antibody	Invitrogen	#31573 RRID:AB2536183	IHC 1:400
Antibody	Fluorescein (FITC)-conjugated goat anti-rabbit IgG secondary antibody	Millipore	#AP307F RRID:AB92652	IHC 1:400
Antibody	Alexa Fluor 568-conjugated goat anti-mouse IgG ₁ secondary antibody	Invitrogen	# A21124 RRID:AB141611	IHC 1:400
Antibody	rhodamine (TRITC) streptavidin secondary antibody	Jackson ImmunoResearch Labs Inc.	#016-020-084 RRID:AB2337237	IHC 1:400
Antibody	Alexa-Fluor 568-conjugated goat anti-rabbit	Invitrogen	#A11011 RRID:AB143157	IHC 1:400

	secondary antibody			
Antibody	Alexa Fluor 488-donkey anti-chicken IgG secondary antibody	Jackson ImmunoResearch Labs Inc.	#703-545-155 RRID:AB2340375	IHC 1:400
other	DAPI stain	Thermo Fisher Scientific	#D1306 RRID:AB2629482	IHC 1:1,000
Reagent	Nissl substance stain	Thermo Fisher Scientific	#N21482 RRID:AB2620170	IHC 1:200
software, algorithm	MetaMorph Image Analysis Software	Molecular Devices	RRID:SCR002368	
software, algorithm	AxioVision Imaging System	Zeiss	RRID:SCR002677	
software, algorithm	Axio Imager	Zeiss		
other	SP8 confocal microscope	Leica Microsystems	RRID:SCR018169	
software, algorithm	Imaris	Bitplane	RRID:SCR007370	
software, algorithm	Adobe Photoshop	Adobe Inc.	RRID:SCR014199	

software, algorithm	PRISM 8.0	GraphPad	RRID:SCR002798	
------------------------	-----------	----------	----------------	--

519

520 *Mice.* All animal care and procedures were conducted in accordance with the National Research
521 Council's Guide for the Care and Use of Laboratory Animals and approved by the Institutional
522 Animal Care and Use Committee at Lewis Katz School of Medicine at Temple University,
523 Philadelphia, PA, USA. Congenic Nogo/OMgp/MAG triple knockout mice were generated by
524 breeding congenic lines of Nogo/OMgp double knockout mice obtained from Dr. Binhai Zheng
525 (University of California at San Diego) and of MAG single knockout mice obtained from Dr. Jae
526 K. Lee (University of Miami). Male and female, 2-3 months old Nogo^{-/-}/OMgp^{-/-}/MAG^{-/-} mice
527 and age-matched C57BL/6J mice (The Jackson Laboratory) were used. Mice were genotyped at
528 the time of weaning by tail clipping and PCR analysis using the primers described in earlier
529 studies (Li et al., 1994; Lee et al., 2010).

530

531 *Dorsal root crush.* Mice were anesthetized with an intraperitoneal injection of xylazine (8
532 mg/kg) and ketamine (120 mg/kg). Supplements were given during the procedure as needed.
533 Following a 2- to 3-cm-long incision in the skin of the back, the spinal musculature was reflected
534 and the L3–S1 spinal cord segments exposed by hemilaminectomies to prepare for unilateral L4–
535 L5 root crush. The cavity made by the laminectomies was perfused with warm sterile Ringer's
536 solution. A small incision was made in the dura overlying the L4 and L5 DR. A fine forceps
537 (Dumont #5; Fine Science Tools, Foster City, CA) was introduced subdurally and the DR
538 crushed for 10 s. To avoid scar formation and possible compression, we applied a piece of thin
539 SILASTIC membrane (Biobrane, Bertek Pharmaceuticals, Sugarland, TX) over the laminectomy
540 site and covered it with a layer of thicker artificial dura (Gore Preclude MVP Dura Substitute,
541 W.L. Gore and Associates, Flagstaff, AZ). The overlying musculature was closed with 5-0
542 sutures, and the skin closed with wound clips. All animals received subcutaneous injections of
543 saline (0.9% w/v NaCl) and buprenorphine (0.05 mg/kg) for postoperative pain management and
544 remained on a heating pad until fully recovered from anesthesia. Mice were perfused 2 or 4
545 weeks after the crush, and axon regeneration was analyzed in cryostat sections or in thin dorsal
546 slice preparations of whole spinal cord.

547

548 *Conditioning lesion by sciatic nerve crush.* DRG neurons were preconditioned by crushing the
549 sciatic nerve in the lateral thigh of the ipsilateral hind leg 10 days before the DRs were crushed.
550 Animals were anesthetized as described above; the skin and superficial muscle layer of the
551 midthigh were opened; and the sciatic nerve was crushed for 10 s with fine forceps (Dumont #5;
552 Fine Science Tools, Foster City, CA). The muscle and skin were then closed in layers and the
553 animals allowed to recover on a heating pad until fully awake.

554
555 *Production and microinjection of AAV2-GFP, LV-chABC and LV-GDNF.* Recombinant self-
556 complementary adeno-associated virus 2 (scAAV2) carrying eGFP was generated by helper
557 virus-free system (Ayuso et al., 2010) as described previously (Liu et al., 2014). Replication
558 deficient lentiviruses encoding either chABC (LV-chABC) or GDNF (LV-GDNF) used a pBOB
559 lentiviral expression vector with CMV-enhanced chicken β -actin (CAG) promoter. The
560 procedures to generate the viruses and their efficacy were described before: LV-chABC (Curinga
561 et al., 2007; Jin et al., 2011; Han et al., 2017); LV-GDNF (Zhang et al., 2009a; Deng et al., 2013;
562 Zhang et al., 2013; Kelamangalath et al., 2015; Han et al., 2017). AAV2-GFP was microinjected
563 into lumbar DRGs using a micropipette pulled to a diameter of 0.05 mm and a nanoinjector
564 (World Precision Instruments, Sarasota, FL). The viruses were injected at the time of DR crush.
565 For each injection, the micropipette was introduced 0.5 mm into the DRG and a total volume of
566 AAV (0.8 μ l) containing $>2 \times 10^{12}$ GC/ml injected over a 10 min period. The glass needle was left
567 in place for 2 min after each injection. For LV-GDNF, five injections of 0.3 μ l lentivirus (a total
568 of 2×10^7 viral particles) were equally spaced rostrocaudally along the L4–L5 DREZ. Injections
569 were made at a rate of 100 nl/min at a depth of 0.25mm from the spinal cord dorsal surface.

570
571 *Tissue processing, selection and immunohistochemistry.* Two or four weeks after DR crush, mice
572 were sacrificed by an overdose of Euthasol and perfused transcardially with 0.9% saline
573 followed by 4% paraformaldehyde (PFA) in 0.1M phosphate buffer (PBS, pH=7.4). The spinal
574 cords with attached dorsal roots and DRGs were removed and examined in wholemounds to
575 exclude those tissues with poor transduction of AAV2-GFP and/or spared axons. Properly
576 lesioned and GFP+ tissues were first examined in wholemounds to assess DR regeneration across
577 the DREZ. Tissues were then processed for analysis on cryostat sections. One or two
578 representative tissues were processed for immunohistochemistry in spinal cord wholemounds.

579 For analysis on cryostat sections, spinal cords were post-fixed in 4% PFA overnight at 4°C and
580 cryoprotected in 30% sucrose for 1-2 days. The tissues were then embedded in M-1 Embedding
581 Matrix (Thermo Fisher Scientific, Waltham, MA), transversely sectioned at 20 µm using a
582 cryostat (Leica Microsystems, Germany), and mounted directly on slides (Superfrost Plus, Fisher
583 Scientific, Pittsburgh, PA). For immunolabeling, sections were rinsed three times in PBS for 30
584 min followed by 10 min incubation with 0.1 M glycine in PBS, and 15 min incubation with 0.2%
585 Triton X-100, 2% bovine serum albumin (BSA) in PBS (TBP). Sections were incubated with
586 primary antibodies overnight at 4°C, washed three times for 30 min with 2% BSA in PBS and
587 incubated with secondary antibodies for 1 h at room temperature. After three rinses with PBS,
588 sections were mounted in Vectashield (Vector Laboratories, Burlingame, CA) and stored at -
589 20°C until examination. For wholemount immunostaining of spinal cords, spinal cords with
590 attached DRs were post-fixed in 4% PFA for 2 h at 4°C and the dura mater removed. The spinal
591 cord was then rinsed three times with PBS for 30 min, incubated for 10 min in 0.1M glycine in
592 2% BSA/PBS, and permeabilized with pre-cooled methanol at -20°C for 10 min. After extensive
593 rinsing in PBS, the spinal cord was incubated with primary antibody diluted in TBP at room
594 temperature overnight, rinsed thoroughly in TBP the following day, and incubated with
595 secondary antibodies for 2 h at room temperature. After rinsing in PBS, a thin slice of dorsal
596 spinal cord (~2 mm thick) with attached DR stumps was cut with a microscissors and mounted
597 on slides in Vectashield (Vector Laboratories, Burlingame, CA).

598
599 *Antibodies.* Primary antibodies were used at the following concentrations for
600 immunohistochemistry: rabbit anti-NF200 (1:500, Sigma, St. Louis, MO, #N4142), IB4-biotin
601 conjugate (1:200, Sigma, St. Louis, MO, #L2140), rabbit anti-CGRP (1:2,000, Peninsula Labs,
602 San Carlos, CA, #T4032), chicken anti-GFP (1:1,000, Avés Labs Inc., Davis, CA, #GFP-1020),
603 rabbit anti-GFAP (1:500, Agilent, Santa Clara, CA, #N1506). Secondary antibodies used were
604 Alexa Fluor 647-goat anti-rabbit IgG (1:400, Invitrogen, , Indianapolis, IN, #31573), Fluorescein
605 (FITC)-conjugated goat anti-rabbit IgG (1:400, Millipore, Temecula, CA, AP307F), Alexa Fluor
606 568-conjugated goat anti-mouse IgG1 (1:400, Invitrogen, Indianapolis, IN, A21124), Alexa-
607 Fluor 568-conjugated goat anti-rabbit (1:400, Invitrogen, Indianapolis, IN, #A11011), rhodamine
608 (TRITC) streptavidin (1:400, Jackson ImmunoResearch Labs Inc., West Grove, PA, #016-020-
609 084), or Alexa Fluor 488-donkey anti-chicken IgG (1:400, Jackson ImmunoResearch Labs Inc.,

610 West Grove, PA, #703-545-155). DAPI nucleic acid stain (1:1000, Thermo Fisher Scientific,
611 Pittsburgh, PA, #D1306) for cell nuclei or Nissl substance stain (1:200, Thermo Fisher
612 Scientific, Pittsburgh, PA, #N21482) for neuronal cells was used to counterstain prior to final
613 wash steps in PBS.

614
615 *Microscopy and image acquisition.* An Olympus BX53 microscope equipped with Orca-R2 CCD
616 camera (Hamamatsu, Japan) controlled by MetaMorph Image Analysis Software (Molecular
617 Devices, San Jose, CA) was used to examine serial cryostat sections and dorsal wholemounts. Z
618 stacked images were acquired using the Axio Imager (Zeiss, Germany) upright fluorescence
619 microscope and AxioVision Imaging System (Zeiss, Germany) software or a SP8 confocal
620 microscope (Leica Microsystems, Buffalo Grove, IL). All images were processed using Imaris
621 (Bitplane, Windsor, CT) and Adobe Photoshop (Adobe Inc. San Jose, CA).

622
623 *Analysis of regeneration across the DREZ.* The location of the DREZ, the transitional zone
624 between the CNS and PNS, was demarcated by GFAP immunostaining of astrocytes. The white
625 dotted lines (e.g., Figure 1D, 1E) approximate the location of the outer (peripheral) border of the
626 DREZ, as defined by GFAP immunolabeling of astrocytic processes that extend peripherally
627 (termed here ‘astrocyte:PNS border’ or ‘astrocytic border’). When GFAP was not
628 immunolabeled, the astrocytic border was approximated based on the greater abundance of cell
629 nuclei in the PNS than CNS. For comparative evaluation of regeneration across the DREZ, we
630 considered that DR axons penetrated into the CNS when they extended at least 100 μ m beyond
631 the astrocyte:PNS border. For quantitative analysis, digital images were captured from 3-6
632 representative, non-adjacent sections taken from L4 and L5 segments of each mouse (n=3-8
633 mice per cohort). A raw image was converted to a binary image using ImageJ with a threshold
634 that appropriately separated GFP and background fluorescence. Lines were drawn at 100 μ m
635 before the border (in PNS territory), at the DREZ outer border, and at 100 μ m intervals into CNS
636 territory. The number of intersections of GFP+ axons at these distances was counted. The
637 number of axons that crossed the outer border was normalized by the number of GFP+ axons
638 counted at 100 μ m before the border in the PNS, and then averaged by the number of evaluated
639 sections and animals. This quantification resulted in the ‘axon number index’ that indicated the
640 relative number and distance of axons that regenerated into the CNS in each group of mice.

641

642 *Statistical analysis.* All statistical analyses were performed using PRISM 8.0 (GraphPad, San
643 Diego, CA.). Statistical analysis was by two-way repeated measures analysis of variance
644 (ANOVA) with Tukey's multiple comparison tests. All data are presented as mean \pm SD. Results
645 were considered statistically significant if the p-value was < 0.05 .

646

647 **COMPETING INTERESTS**

648 The authors declare no competing financial interests.

649

650 **ACKNOWLEDGMENTS**

651 We thank Drs. Alan Tessler, Matt Grove and Harun Noristani for critical reading of the
652 manuscript. We greatly thank Dr. Binhai Zheng for Nogo/MAG/OMgp triple and Nogo/OMgp
653 double knockout mice, Dr. Jae Lee for MAG mutant mice, and Yingpeng Liu for technical
654 assistance with LV-chABC and LV-GDNF.

655

656 **FUNDINGS**

657 This work was supported by NIH NINDS (NS079631) and Shriners Hospitals for Children
658 (86600, 84050) to Y.-J.S.

659

660

661 **REFERENCES**

662

663 Andrews, M. R., Czvitkovich, S., Dassie, E., Vogelaar, C. F., Faissner, A., Blits, B., Gage, F. H.,
664 ffrench-Constant, C., and Fawcett, J. W. (2009). Alpha9 integrin promotes neurite
665 outgrowth on tenascin-C and enhances sensory axon regeneration. *J Neurosci*, 29(17),
666 5546-5557. doi:29/17/5546 [pii] 10.1523/JNEUROSCI.0759-09.2009

667 Ayuso, E., Mingozzi, F., and Bosch, F. (2010). Production, purification and characterization of
668 adeno-associated vectors. *Curr Gene Ther*, 10(6), 423-436.

669 Blesch, A., Lu, P., Tsukada, S., Alto, L. T., Roet, K., Coppola, G., Geschwind, D., and
670 Tuszynski, M. H. (2012). Conditioning lesions before or after spinal cord injury recruit

- 671 broad genetic mechanisms that sustain axonal regeneration: superiority to camp-mediated
672 effects. *Exp Neurol*, 235(1), 162-173. doi:10.1016/j.expneurol.2011.12.037
- 673 Cafferty, W. B., Bradbury, E. J., Lidierth, M., Jones, M., Duffy, P. J., Pezet, S., and McMahon,
674 S. B. (2008). Chondroitinase ABC-mediated plasticity of spinal sensory function. *J*
675 *Neurosci*, 28(46), 11998-12009. doi:10.1523/jneurosci.3877-08.2008
- 676 Cafferty, W. B., Yang, S. H., Duffy, P. J., Li, S., and Strittmatter, S. M. (2007). Functional
677 axonal regeneration through astrocytic scar genetically modified to digest chondroitin
678 sulfate proteoglycans. *J Neurosci*, 27(9), 2176-2185. doi:10.1523/jneurosci.5176-06.2007
- 679 Carlstedt, T. (1985). Regenerating axons form nerve terminals at astrocytes. *Brain Res*, 347(1),
680 188-191. doi:0006-8993(85)90911-4 [pii]
- 681 Carlstedt, T. (2008). Root repair review: basic science background and clinical outcome. *Restor*
682 *Neurol Neurosci*, 26(2-3), 225-241.
- 683 Cheah, M., Andrews, M. R., Chew, D. J., Moloney, E. B., Verhaagen, J., Fässler, R., and
684 Fawcett, J. W. (2016). Expression of an Activated Integrin Promotes Long-Distance
685 Sensory Axon Regeneration in the Spinal Cord. *J Neurosci*, 36(27), 7283-7297.
686 doi:10.1523/jneurosci.0901-16.2016
- 687 Chong, M. S., Woolf, C. J., Haque, N. S. K., and Anderson, P. N. (1999). Axonal regeneration
688 from injured dorsal roots into the spinal cord of adult rats. *Journal of Comparative*
689 *Neurology*, 410(1), 42-54.
- 690 Collins, A., Ibrahim, A., Li, D., Liadi, M., and Li, Y. (2019). Reconstruction of the Damaged
691 Dorsal Root Entry Zone by Transplantation of Olfactory Ensheathing Cells. *Cell*
692 *Transplant*, 28(9-10), 1212-1219. doi:10.1177/0963689719855938
- 693 Curinga, G. M., Snow, D. M., Mashburn, C., Kohler, K., Thobaben, R., Caggiano, A. O., and
694 Smith, G. M. (2007). Mammalian-produced chondroitinase AC mitigates axon inhibition
695 by chondroitin sulfate proteoglycans. *J Neurochem*, 102(1), 275-288. doi:JNC4530
696 [pii]10.1111/j.1471-4159.2007.04530.x

- 697 Deng, L. X., Deng, P., Ruan, Y., Xu, Z. C., Liu, N. K., Wen, X., Smith, G. M., and Xu, X. M.
698 (2013). A novel growth-promoting pathway formed by GDNF-overexpressing Schwann
699 cells promotes propriospinal axonal regeneration, synapse formation, and partial recovery
700 of function after spinal cord injury. *J Neurosci*, 33(13), 5655-5667.
701 doi:10.1523/jneurosci.2973-12.2013
- 702 DePaul, M. A., Lin, C. Y., Silver, J., and Lee, Y. S. (2017). Combinatory repair strategy to
703 promote axon regeneration and functional recovery after chronic spinal cord injury. *Sci*
704 *Rep*, 7(1), 9018. doi:10.1038/s41598-017-09432-6
- 705 Di Maio, A., Skuba, A., Himes, B. T., Bhagat, S. L., Hyun, J. K., Tessler, A., Bishop, D., and
706 Son, Y. J. (2011). In Vivo Imaging of Dorsal Root Regeneration: Rapid Immobilization
707 and Presynaptic Differentiation at the CNS/PNS Border. *J Neurosci*, 31(12), 4569-4582.
708 doi:10.1523/JNEUROSCI.4638-10.2011
- 709 10.1523/JNEUROSCI.4638-10.2011
- 710 Dickendesher, T. L., Baldwin, K. T., Mironova, Y. A., Koriyama, Y., Raiker, S. J., Askew, K.
711 L., Wood, A., Geoffroy, C. G., Zheng, B., Liepmann, C. D., Katagiri, Y., Benowitz, L. I.,
712 Geller, H. M., and Giger, R. J. (2012). NgR1 and NgR3 are receptors for chondroitin
713 sulfate proteoglycans. *Nat Neurosci*, 15(5), 703-712. doi:10.1038/nn.3070
- 714 El-Brolosy, M. A., and Stainier, D. Y. R. (2017). Genetic compensation: A phenomenon in
715 search of mechanisms. *PLoS Genet*, 13(7), e1006780. doi:10.1371/journal.pgen.1006780
- 716 Fink, K. L., Strittmatter, S. M., and Cafferty, W. B. (2015). Comprehensive Corticospinal
717 Labeling with mu-crystallin Transgene Reveals Axon Regeneration after Spinal Cord
718 Trauma in *ngr1*^{-/-} Mice. *J Neurosci*, 35(46), 15403-15418. doi:10.1523/jneurosci.3165-
719 15.2015
- 720 Fischer, G., Kostic, S., Nakai, H., Park, F., Sapunar, D., Yu, H., and Hogan, Q. (2011). Direct
721 injection into the dorsal root ganglion: technical, behavioral, and histological
722 observations. *J Neurosci Methods*, 199(1), 43-55. doi:10.1016/j.jneumeth.2011.04.021

- 723 Golding, J. P., Bird, C., McMahon, S., and Cohen, J. (1999). Behaviour of DRG sensory neurites
724 at the intact and injured adult rat dorsal root entry zone: postnatal neurites become
725 paralysed, whilst injury improves the growth of embryonic neurites. *Glia*, 26(4), 309-323.
726 doi:10.1002/(SICI)1098-1136(199906)26:4<309::AID-GLIA5>3.0.CO;2-0 [pii]
- 727 Golding, J. P., Shewan, D., Berry, M., and Cohen, J. (1996). An in vitro model of the rat dorsal
728 root entry zone reveals developmental changes in the extent of sensory axon growth into
729 the spinal cord. *Molecular and Cellular Neuroscience*, 7(3), 191-203.
730 doi:10.1006/mcne.1996.0015
- 731 Griffin, J. M., and Bradke, F. (2020). Therapeutic repair for spinal cord injury: combinatory
732 approaches to address a multifaceted problem. *EMBO Mol Med*, 12(3), e11505.
733 doi:10.15252/emmm.201911505
- 734 Guo, W. L., Qu, W. R., Zeng, L. N., Qi, Z. P., Huang, C., Zhu, Z., and Li, R. (2019). l-Theanine
735 and NEP1-40 promote nerve regeneration and functional recovery after brachial plexus
736 root avulsion. *Biochem Biophys Res Commun*, 508(4), 1126-1132.
737 doi:10.1016/j.bbrc.2018.11.124
- 738 Guseva, D., and Chelyshev, Y. (2006). The Plasticity of the DRG Neurons Belonging to
739 Different Subpopulations After Dorsal Rhizotomy. *Cell Mol Neurobiol*, 26(7-8), 1223-
740 1232.
- 741 Han, S. B., Kim, H., Lee, H., Grove, M., Smith, G. M., and Son, Y. J. (2017). Postinjury
742 Induction of Activated ErbB2 Selectively Hyperactivates Denervated Schwann Cells and
743 Promotes Robust Dorsal Root Axon Regeneration. *J Neurosci*, 37(45), 10955-10970.
744 doi:10.1523/JNEUROSCI.0903-17.2017
- 745 Han, S. B., Kim, H., Skuba, A., Tessler, A., Ferguson, T., and Son, Y. J. (2012). Sensory Axon
746 Regeneration: A Review from an in vivo Imaging Perspective. *Exp Neurobiol*, 21(3), 83-
747 93. doi:10.5607/en.2012.21.3.83

- 748 Harvey, P. A., Lee, D. H., Qian, F., Weinreb, P. H., and Frank, E. (2009). Blockade of Nogo
749 receptor ligands promotes functional regeneration of sensory axons after dorsal root
750 crush. *J Neurosci*, 29(19), 6285-6295. doi:10.1523/jneurosci.5885-08.2009
- 751 Ito, S., Nagoshi, N., Tsuji, O., Shibata, S., Shinozaki, M., Kawabata, S., Kojima, K., Yasutake,
752 K., Hirokawa, T., Matsumoto, M., Takei, K., Nakamura, M., and Okano, H. (2018).
753 LOTUS Inhibits Neuronal Apoptosis and Promotes Tract Regeneration in Contusive
754 Spinal Cord Injury Model Mice. *eNeuro*, 5(5). doi:10.1523/eneuro.0303-18.2018
- 755 Iwakawa, M., Mizoi, K., Tessler, A., and Itoh, Y. (2001). Intraspinally implanted fibrin glue
756 containing glial cell line-derived neurotrophic factor promote dorsal root regeneration
757 into spinal cord. *Neurorehabil Neural Repair*, 15(3), 173-182.
758 doi:10.1177/154596830101500304
- 759 Jacques, S. J., Ahmed, Z., Forbes, A., Douglas, M. R., Vignesswara, V., Berry, M., and Logan, A.
760 (2012). AAV8(gfp) preferentially targets large diameter dorsal root ganglion neurones
761 after both intra-dorsal root ganglion and intrathecal injection. *Mol Cell Neurosci*, 49(4),
762 464-474. doi:10.1016/j.mcn.2012.03.002
- 763 Jin, Y., Ketschek, A., Jiang, Z., Smith, G., and Fischer, I. (2011). Chondroitinase activity can be
764 transduced by a lentiviral vector in vitro and in vivo. *J Neurosci Methods*, 199(2), 208-
765 213. doi:10.1016/j.jneumeth.2011.05.007
- 766 Kaiser, R., Waldauf, P., Ullas, G., and Krajcovicová, A. (2020). Epidemiology, etiology, and types of
767 severe adult brachial plexus injuries requiring surgical repair: systematic review and
768 meta-analysis. *Neurosurg Rev*, 43(2), 443-452. doi:10.1007/s10143-018-1009-2
- 769 Kelamangalath, L., Tang, X., Bezik, K., Sterling, N., Son, Y. J., and Smith, G. M. (2015).
770 Neurotrophin selectivity in organizing topographic regeneration of nociceptive afferents.
771 *Exp Neurol*, 271, 262-278. doi:10.1016/j.expneurol.2015.06.007
- 772 Kubota, S., Sidikejiang, W., Kudo, M., Inoue, K. I., Umeda, T., Takada, M., and Seki, K. (2019).
773 Optogenetic recruitment of spinal reflex pathways from large-diameter primary afferents

- 774 in non-transgenic rats transduced with AAV9/Channelrhodopsin 2. *J Physiol*, 597(19),
775 5025-5040. doi:10.1113/jp278292
- 776 Kwon, M. J., Shin, H. Y., Cui, Y., Kim, H., Thi, A. H., Choi, J. Y., Kim, E. Y., Hwang, D. H.,
777 and Kim, B. G. (2015). CCL2 Mediates Neuron-Macrophage Interactions to Drive
778 Proregenerative Macrophage Activation Following Preconditioning Injury. *J Neurosci*,
779 35(48), 15934-15947. doi:10.1523/jneurosci.1924-15.2015
- 780 Lang, B. T., Cregg, J. M., DePaul, M. A., Tran, A. P., Xu, K., Dyck, S. M., Madalena, K. M.,
781 Brown, B. P., Weng, Y. L., Li, S., Karimi-Abdolrezaee, S., Busch, S. A., Shen, Y., and
782 Silver, J. (2015). Modulation of the proteoglycan receptor PTP σ promotes recovery after
783 spinal cord injury. *Nature*, 518(7539), 404-408. doi:10.1038/nature13974
- 784 Lee, D. H., and Lee, J. K. (2013). Animal models of axon regeneration after spinal cord injury.
785 *Neurosci Bull*, 29(4), 436-444. doi:10.1007/s12264-013-1365-4
- 786 Lee, J. K., Geoffroy, C. G., Chan, A. F., Tolentino, K. E., Crawford, M. J., Leal, M. A., Kang,
787 B., and Zheng, B. H. (2010). Assessing Spinal Axon Regeneration and Sprouting in
788 Nogo-, MAG-, and OMgp-Deficient Mice. *Neuron*, 66(5), 663-670.
789 doi:10.1016/j.neuron.2010.05.002
- 790 Lemons, M. L., Sandy, J. D., Anderson, D. K., and Howland, D. R. (2003). Intact aggrecan and
791 chondroitin sulfate-depleted aggrecan core glycoprotein inhibit axon growth in the adult
792 rat spinal cord. *Exp Neurol*, 184(2), 981-990. doi:10.1016/s0014-4886(03)00383-2
- 793 Li, C., Tropak, M. B., Gerlai, R., Clapoff, S., Abramow-Newerly, W., Trapp, B., Peterson, A.,
794 and Roder, J. (1994). Myelination in the absence of myelin-associated glycoprotein.
795 *Nature*, 369(6483), 747-750. doi:10.1038/369747a0
- 796 Li, C. L., Li, K. C., Wu, D., Chen, Y., Luo, H., Zhao, J. R., Wang, S. S., Sun, M. M., Lu, Y. J.,
797 Zhong, Y. Q., Hu, X. Y., Hou, R., Zhou, B. B., Bao, L., Xiao, H. S., and Zhang, X.
798 (2016). Somatosensory neuron types identified by high-coverage single-cell RNA-
799 sequencing and functional heterogeneity. *Cell Res*, 26(8), 967. doi:10.1038/cr.2016.90

- 800 Li, M., Shibata, A., Li, C., Braun, P. E., McKerracher, L., Roder, J., Kater, S. B., and David, S.
801 (1996). Myelin-associated glycoprotein inhibits neurite/axon growth and causes growth
802 cone collapse. *J Neurosci Res*, 46(4), 404-414. doi:10.1002/(SICI)1097-
803 4547(19961115)46:4<404::AID-JNR2>3.0.CO;2-K [pii]10.1002/(SICI)1097-
804 4547(19961115)46:4<404::AID-JNR2>3.0.CO;2-K
- 805 Li, S., Xue, C., Yuan, Y., Zhang, R., Wang, Y., Wang, Y., Yu, B., Liu, J., Ding, F., Yang, Y.,
806 and Gu, X. (2015). The transcriptional landscape of dorsal root ganglia after sciatic nerve
807 transection. *Sci Rep*, 5, 16888. doi:10.1038/srep16888
- 808 Li, Y., Carlstedt, T., Berthold, C. H., and Raisman, G. (2004). Interaction of transplanted
809 olfactory-ensheathing cells and host astrocytic processes provides a bridge for axons to
810 regenerate across the dorsal root entry zone. *Exp Neurol*, 188(2), 300-308.
811 doi:10.1016/j.expneurol.2004.04.021
- 812 Lin, C. L., Heron, P., Hamann, S. R., and Smith, G. M. (2014). Functional distinction between
813 NGF-mediated plasticity and regeneration of nociceptive axons within the spinal cord.
814 *Neuroscience*, 272, 76-87. doi:10.1016/j.neuroscience.2014.04.053
- 815 Lindholm, T., Risling, M., Carlstedt, T., Hammarberg, H., Wallquist, W., Cullheim, S., and
816 Sköld, M. K. (2017). Expression of Semaphorins, Neuropilins, VEGF, and Tenascins in
817 Rat and Human Primary Sensory Neurons after a Dorsal Root Injury. *Front Neurol*, 8, 49.
818 doi:10.3389/fneur.2017.00049
- 819 Liu, S., Bohl, D., Blanchard, S., Bacci, J., Saïd, G., and Heard, J. M. (2009). Combination of
820 microsurgery and gene therapy for spinal dorsal root injury repair. *Mol Ther*, 17(6), 992-
821 1002. doi:10.1038/mt.2009.23
- 822 Liu, Y., Keefe, K., Tang, X., Lin, S., and Smith, G. M. (2014). Use of self-complementary
823 adeno-associated virus serotype 2 as a tracer for labeling axons: implications for axon
824 regeneration. *PLoS ONE*, 9(2), e87447. doi:10.1371/journal.pone.0087447
- 825 Liu, Y., Kelamangalath, L., Kim, H., Han, S. B., Tang, X., Zhai, J., Hong, J. W., Lin, S., Son, Y.
826 J., and Smith, G. M. (2016). NT-3 promotes proprioceptive axon regeneration when

- 827 combined with activation of the mTor intrinsic growth pathway but not with reduction of
828 myelin extrinsic inhibitors. *Exp Neurol*, 283(Pt A), 73-84.
829 doi:10.1016/j.expneurol.2016.05.021
- 830 Liuzzi, F. J., and Lasek, R. J. (1987). Astrocytes block axonal regeneration in mammals by
831 activating the physiological stop pathway. *Science*, 237(4815), 642-645.
- 832 Mar, F. M., Simões, A. R., Rodrigo, I. S., and Sousa, M. M. (2016). Inhibitory Injury Signaling
833 Represses Axon Regeneration After Dorsal Root Injury. *Mol Neurobiol*, 53(7), 4596-
834 4605. doi:10.1007/s12035-015-9397-6
- 835 Mason, M. R. J., Ehlert, E. M. E., Eggers, R., Pool, C. W., Hermening, S., Huseinovic, A.,
836 Timmermans, E., Blits, B., and Verhaagen, J. (2010). Comparison of AAV Serotypes for
837 Gene Delivery to Dorsal Root Ganglion Neurons. *Molecular Therapy*, 18(4), 715-724.
838 doi:10.1038/mt.2010.19
- 839 Montagutelli, X. (2000). Effect of the genetic background on the phenotype of mouse mutations.
840 *J Am Soc Nephrol*, 11 Suppl 16, S101-105.
- 841 Muir, E., De Winter, F., Verhaagen, J., and Fawcett, J. (2019). Recent advances in the
842 therapeutic uses of chondroitinase ABC. *Exp Neurol*, 321, 113032.
843 doi:10.1016/j.expneurol.2019.113032
- 844 Neumann, S., and Woolf, C. J. (1999). Regeneration of dorsal column fibers into and beyond the
845 lesion site following adult spinal cord injury. *Neuron*, 23(1), 83-91. doi:S0896-
846 6273(00)80755-2 [pii]
- 847 Nichols, E. L., and Smith, C. J. (2020). Functional Regeneration of the Sensory Root via Axonal
848 Invasion. *Cell Rep*, 30(1), 9-17.e13. doi:10.1016/j.celrep.2019.12.008
- 849 Niu, J., Ding, L., Li, J. J., Kim, H., Liu, J., Li, H., Moberly, A., Badea, T. C., Duncan, I. D., Son,
850 Y. J., Scherer, S. S., and Luo, W. (2013). Modality-based organization of ascending
851 somatosensory axons in the direct dorsal column pathway. *J Neurosci*, 33(45), 17691-
852 17709. doi:10.1523/JNEUROSCI.3429-13.2013

- 853 O'Donovan, K. J., Ma, K., Guo, H., Wang, C., Sun, F., Han, S. B., Kim, H., Wong, J. K.,
854 Charron, J., Zou, H., Son, Y. J., He, Z., and Zhong, J. (2014). B-RAF kinase drives
855 developmental axon growth and promotes axon regeneration in the injured mature CNS.
856 *J Exp Med*, 211(5), 801-814. doi:10.1084/jem.20131780
- 857 O'Shea, T. M., Burda, J. E., and Sofroniew, M. V. (2017). Cell biology of spinal cord injury and
858 repair. *J Clin Invest*, 127(9), 3259-3270. doi:10.1172/jci90608
- 859 Ohtake, Y., Saito, A., and Li, S. (2018). Diverse functions of protein tyrosine phosphatase σ in
860 the nervous and immune systems. *Exp Neurol*, 302, 196-204.
861 doi:10.1016/j.expneurol.2018.01.014
- 862 Palmisano, I., Danzi, M. C., Hutson, T. H., Zhou, L., McLachlan, E., Serger, E., Shkura, K.,
863 Srivastava, P. K., Hervera, A., Neill, N. O., Liu, T., Dhrif, H., Wang, Z., Kubat, M.,
864 Wuchty, S., Merckenschlager, M., Levi, L., Elliott, E., Bixby, J. L., Lemmon, V. P., and
865 Di Giovanni, S. (2019). Epigenomic signatures underpin the axonal regenerative ability
866 of dorsal root ganglia sensory neurons. *Nat Neurosci*, 22(11), 1913-1924.
867 doi:10.1038/s41593-019-0490-4
- 868 Peng, X., Zhou, Z., Hu, J., Fink, D. J., and Mata, M. (2010). Soluble Nogo receptor down-
869 regulates expression of neuronal Nogo-A to enhance axonal regeneration. *J Biol Chem*,
870 285(4), 2783-2795. doi:10.1074/jbc.M109.046425
- 871 Quaglia, X., Beggah, A. T., Seidenbecher, C., and Zurn, A. D. (2008). Delayed priming
872 promotes CNS regeneration post-rhizotomy in Neurocan and Brevican-deficient mice.
873 *Brain*, 131(Pt 1), 240-249. doi:10.1093/brain/awm279
- 874 Ramer, M. S., Duraisingam, I., Priestley, J. V., and McMahon, S. B. (2001). Two-tiered
875 inhibition of axon regeneration at the dorsal root entry zone. *The Journal of*
876 *neuroscience : the official journal of the Society for Neuroscience*, 21(8), 2651-2660.
- 877 Ramer, M. S., Priestley, J. V., and McMahon, S. B. (2000). Functional regeneration of sensory
878 axons into the adult spinal cord. *Nature*, 403(6767), 312-316. doi:10.1038/35002084

- 879 Smith, G. M., Falone, A. E., and Frank, E. (2012). Sensory axon regeneration: rebuilding
880 functional connections in the spinal cord. *Trends Neurosci*, 35(3), 156-163.
881 doi:10.1016/j.tins.2011.10.006
- 882 Son, Y. J. (2015). Synapsing with NG2 cells (polydendrocytes), unappreciated barrier to axon
883 regeneration? *Neural Regen Res*, 10(3), 346-348. doi:10.4103/1673-5374.153672
- 884 Steinmetz, M. P., Horn, K. P., Tom, V. J., Miller, J. H., Busch, S. A., Nair, D., Silver, D. J., and
885 Silver, J. (2005). Chronic enhancement of the intrinsic growth capacity of sensory
886 neurons combined with the degradation of inhibitory proteoglycans allows functional
887 regeneration of sensory axons through the dorsal root entry zone in the mammalian spinal
888 cord. *J Neurosci*, 25(35), 8066-8076. doi:10.1523/jneurosci.2111-05.2005
- 889 Stensaas, L. J., Partlow, L. M., Burgess, P. R., and Horch, K. W. (1987). Inhibition of
890 regeneration: the ultrastructure of reactive astrocytes and abortive axon terminals in the
891 transition zone of the dorsal root. *Prog Brain Res*, 71, 457-468. doi:10.1016/s0079-
892 6123(08)61846-4
- 893 Steward, O., Popovich, P. G., Dietrich, W. D., and Kleitman, N. (2012). Replication and
894 reproducibility in spinal cord injury research. *Exp Neurol*, 233(2), 597-605.
895 doi:10.1016/j.expneurol.2011.06.017
- 896 Steward, O., Zheng, B., and Tessier-Lavigne, M. (2003). False resurrections: distinguishing
897 regenerated from spared axons in the injured central nervous system. *J Comp Neurol*,
898 459(1), 1-8. doi:10.1002/cne.10593
- 899 Tan, C. L., Kwok, J. C., Patani, R., Ffrench-Constant, C., Chandran, S., and Fawcett, J. W.
900 (2011). Integrin activation promotes axon growth on inhibitory chondroitin sulfate
901 proteoglycans by enhancing integrin signaling. *J Neurosci*, 31(17), 6289-6295.
902 doi:10.1523/jneurosci.0008-11.2011
- 903 Tedeschi, A., Omura, T., and Costigan, M. (2017). CNS repair and axon regeneration: Using
904 genetic variation to determine mechanisms. *Exp Neurol*, 287(Pt 3), 409-422.
905 doi:10.1016/j.expneurol.2016.05.004

- 906 Tessler, A., Himes, B. T., Houle, J., and Reier, P. J. (1988). Regeneration of adult dorsal root
907 axons into transplants of embryonic spinal cord. *J Comp Neurol*, 270(4), 537-548.
908 doi:10.1002/cne.902700407
- 909 Thiede-Stan, N. K., and Schwab, M. E. (2015). Attractive and repulsive factors act through
910 multi-subunit receptor complexes to regulate nerve fiber growth. *J Cell Sci*, 128(14),
911 2403-2414. doi:10.1242/jcs.165555
- 912 Tom, V. J., Steinmetz, M. P., Miller, J. H., Doller, C. M., and Silver, J. (2004). Studies on the
913 development and behavior of the dystrophic growth cone, the hallmark of regeneration
914 failure, in an in vitro model of the glial scar and after spinal cord injury. *J Neurosci*,
915 24(29), 6531-6539. doi:10.1523/JNEUROSCI.0994-04.2004 24/29/6531 [pii]
- 916 Vargas, M. E., and Barres, B. A. (2007). Why is Wallerian degeneration in the CNS so slow?
917 *Annu Rev Neurosci*, 30, 153-179. doi:10.1146/annurev.neuro.30.051606.094354
- 918 Wang, R., King, T., Ossipov, M. H., Rossomando, A. J., Vanderah, T. W., Harvey, P., Cariani,
919 P., Frank, E., Sah, D. W., and Porreca, F. (2008). Persistent restoration of sensory
920 function by immediate or delayed systemic artemin after dorsal root injury. *Nat Neurosci*,
921 11(4), 488-496. doi:10.1038/nn2069
- 922 Wang, X., Hasan, O., Arzeno, A., Benowitz, L. I., Cafferty, W. B., and Strittmatter, S. M.
923 (2012). Axonal regeneration induced by blockade of glial inhibitors coupled with
924 activation of intrinsic neuronal growth pathways. *Exp Neurol*, 237(1), 55-69.
925 doi:10.1016/j.expneurol.2012.06.009
- 926 Wu, D., Klaw, M. C., Connors, T., Kholodilov, N., Burke, R. E., Côté, M. P., and Tom, V. J.
927 (2017). Combining Constitutively Active Rheb Expression and Chondroitinase Promotes
928 Functional Axonal Regeneration after Cervical Spinal Cord Injury. *Mol Ther*, 25(12),
929 2715-2726. doi:10.1016/j.ymthe.2017.08.011
- 930 Wu, D., Klaw, M. C., Kholodilov, N., Burke, R. E., Detloff, M. R., Côté, M. P., and Tom, V. J.
931 (2016). Expressing Constitutively Active Rheb in Adult Dorsal Root Ganglion Neurons
932 Enhances the Integration of Sensory Axons that Regenerate Across a Chondroitinase-

- 933 Treated Dorsal Root Entry Zone Following Dorsal Root Crush. *Front Mol Neurosci*, 9,
934 49. doi:10.3389/fnmol.2016.00049
- 935 Yao, M., Sun, H., Yuan, Q., Li, N., Li, H., Tang, Y., Leung, G. K., and Wu, W. (2019).
936 Targeting proteoglycan receptor PTP σ restores sensory function after spinal cord dorsal
937 root injury by activation of Erks/CREB signaling pathway. *Neuropharmacology*, 144,
938 208-218. doi:10.1016/j.neuropharm.2018.10.035
- 939 Yu, H., Fischer, G., Ferhatovic, L., Fan, F., Light, A. R., Weihrauch, D., Sapunar, D., Nakai, H.,
940 Park, F., and Hogan, Q. H. (2013). Intraganglionic AAV6 results in efficient and long-
941 term gene transfer to peripheral sensory nervous system in adult rats. *PLoS ONE*, 8(4),
942 e61266. doi:10.1371/journal.pone.0061266
- 943 Zhang, C., Jin, Y., Ziemba, K. S., Fletcher, A. M., Ghosh, B., Truit, E., Yurek, D. M., and Smith,
944 G. M. (2013). Long distance directional growth of dopaminergic axons along pathways
945 of netrin-1 and GDNF. *Exp Neurol*, 250, 156-164. doi:10.1016/j.expneurol.2013.09.022
- 946 Zhang, L., Ma, Z., Smith, G. M., Wen, X., Pressman, Y., Wood, P. M., and Xu, X. M. (2009a).
947 GDNF-enhanced axonal regeneration and myelination following spinal cord injury is
948 mediated by primary effects on neurons. *Glia*, 57(11), 1178-1191.
949 doi:10.1002/glia.20840
- 950 Zhang, L., Zheng, S., Wu, H., Wu, Y., Liu, S., Fan, M., and Zhang, J. (2009b). Identification of
951 BLYS (B lymphocyte stimulator), a non-myelin-associated protein, as a functional ligand
952 for Nogo-66 receptor. *J Neurosci*, 29(19), 6348-6352. doi:10.1523/jneurosci.5040-
953 08.2009
- 954 Zhang, Y., Zhang, X., Wu, D., Verhaagen, J., Richardson, P. M., Yeh, J., and Bo, X. (2007).
955 Lentiviral-mediated expression of polysialic acid in spinal cord and conditioning lesion
956 promote regeneration of sensory axons into spinal cord. *Mol Ther*, 15(10), 1796-1804.
- 957
- 958
- 959

960 **FIGURE LEGENDS**

961 **Figure 1. Intraganglionic AAV2-GFP labels proprioceptive and mechanoreceptive axons**

962 (A) Schematic illustration of intraganglionic injection of scAAV2-eGFP and a representative
963 DRG showing infected neurons expressing GFP at 2 weeks post-injection. (B) Mice expressing
964 GFP in >70% Nissl-stained neurons were used in the present study. (C) DRG transverse sections
965 showing GFP+ neurons (arrows) co-expressing neurofilament (NF), IB4, or CGRP. (D)
966 Quantitative comparisons of AAV2-GFP infected neurons illustrating preferential labeling of
967 large-diameter myelinated NF+ neurons, which mediate proprioception and mechanoreception.
968 n>20 sections, 3 mice. (E) A transverse section showing GFP+ axons along the root and within
969 the right side of the spinal cord, projecting into dorsal column, deeper laminae of the dorsal horn
970 and into the ventral horn. An arrow denotes superficial laminae I-IIi lacking GFP fluorescence.
971 (E', E'') Enlarged views of the superficial dorsal horn, illustrating lack of GFP-fluorescence
972 where CGRP+ nociceptive axons (magenta) innervate. DH, dorsal horn; DR, dorsal root; VH;
973 ventral horn. Scale bars=50µm (A, C, E', E''), 200µm (E).

974

975 **Figure 2. Additional strategies for complete lesions and evaluation of DR regeneration**

976 DR regeneration in adult wildtype mice assessed in wholemounts (A-D) and transverse sections
977 (E, F) 2 weeks after L4 and L5 DR crush. (A) Schematic illustration of crushing roots prior to
978 intraganglionic AAV2-GFP injections to avoid labeling of degenerating distal stump axons. (B)
979 Wholemount view of completely crushed L4 and L5 DRs illustrating hundreds of GFP+ axons
980 terminated at the entrance of spinal cord. (B', B'') Enlarged views illustrating most axons
981 terminated near the border. (C-C'') Wholemount views of incompletely crushed DRs showing
982 spared axons with long intraspinal projections. Spared axons are easily detectable in
983 wholemounts and commonly observed in the outermost dorsal rootlets (arrows). (D)
984 Wholemount view of L4 DREZ illustrating GFP+ axons that crossed the astrocyte:PNS border
985 (dotted line) and terminated nearby. The astrocytic border is identified by GFAP immunostaining
986 of astrocytes (red). Yellow line denotes spinal cord midline recognized by the midline vein. (E)
987 Four-color immunolabeling of transverse sections illustrating limited penetration of GFP+ or
988 CGRP+ axons through the DREZ. White dotted lines approximate the peripheral border of the
989 DREZ (astrocyte:PNS border) by locating peripherally projecting astrocytic processes (red) or by
990 greater abundance of cell nuclei in the PNS (blue). Axons rarely extended >200µm beyond the

991 border. Arrowheads denote frequently observed axons that grew along the growth-permissive
992 dura. Arrow denotes occasionally observed subdural axons located several hundred microns past
993 the border. **(F)** Quantitative analysis of DR regeneration on transverse sections (13 sections, 3
994 mice). ~90% GFP+ axons terminated within ~100 μ m of the border. Axons growing farther than
995 100 μ m are considered as having penetrated the DREZ. DH, dorsal horn; DR, dorsal root; S.C.,
996 spinal cord. Scale bars=200 μ m **(B-B”, C-C”, D, E)**.

997

998 **Figure 3. Genetic deletion of Nogo/MAG/OMgp elicits little intraspinal regeneration**

999 DR regeneration in Nogo/MAG/OMgp tKO mice assessed in wholemounds **(C)** or transverse
1000 sections **(D, F)** 2 weeks after L4 and L5 DR crush. **(A)** Identification of triple null mutants (red)
1001 lacking Nogo (A, B, C), MAG and OMgp. **(B)** Schematic illustration of the experimental
1002 procedures. **(C)** Wholemound views of L4-L5 DREZ illustrating termination of hundreds of
1003 GFP+ axons near the astrocyte:PNS border (dotted line), as in wildtype mice. The astrocytic
1004 border is identified by GFAP immunostaining of astrocytes (red). **(C’, C”)** Enlarged views of L4
1005 and L5 DREZ in **(C)**. Arrows denote axons extending longer processes past the DREZ, which
1006 were also frequently observed in wildtype mice. **(D)** Representative transverse sections
1007 illustrating little if any enhanced regeneration of GFP+ axons across the DREZ. Arrows denote
1008 axons that grew dorsally along the pia matter, as also observed in wildtype mice. **(E)**
1009 Quantitative comparisons illustrating no significant difference in WT and Nogo/MAG/OMgp
1010 tKO mice. 100 μ m, p=0.9738, df=162; 200 μ m, p=0.5046, df=162; 300 μ m, p=0.1454, df=162.
1011 Two-way repeated-measures ANOVA with Sidak’s multiple comparisons test (WT: 13 sections,
1012 3 mice; tKO: 16 sections, 5 mice). S.C., spinal cord; ns, not significant. Scale bars=200 μ m **(C-**
1013 **C”, D-D”)**.

1014

1015 **Figure 4. Additional CSPG removal enables minimal intraspinal regeneration in tKO** 1016 **myelin mutants**

1017 DR regeneration in ChABC-expressed Nogo/MAG/OMgp tKO mice assessed in wholemounds
1018 **(B)** and transverse sections **(D, C)** 2 weeks after L4 and L5 DR crush. **(A)** Schematic illustration
1019 of the experimental procedures. LV-ChABC was injected into ipsilateral dorsal horn at multiple
1020 locations rostrocaudally along the L4-L5 DREZ. **(B)** Wholemound views of a ChABC-expressed
1021 tKO showing hundreds of GFP+ axons in L4 and L5 roots terminated near the astrocyte:PNS

1022 border (dotted line), as in WT and tKO mice. The astrocytic border is identified by GFAP
1023 immunostaining of astrocytes (red). **(C)** Representative transverse sections illustrating effective
1024 degradation of CSPGs and modestly enhanced intraspinal regeneration. CS-56 immunoreactivity
1025 is very low in ipsilateral dorsal horn (asterisks), indicating effective removal of inhibitory GAG
1026 chains of CSPGs. Arrowheads denote Schwann cell-associated CS-56 immunoreactivity, which
1027 is markedly reduced but discernable in ChABC-expressed tKO. **(C')** Enlarged views showing a
1028 few GFP+ axons that penetrated the DREZ and are located at the top of the dorsal horn (arrows);
1029 such axons were not observed in WT or Nogo/MAG/OMgp tKO mice. **(D)** Quantitative
1030 comparisons illustrating modestly improved regeneration in ChABC-expressed
1031 Nogo/MAG/OMgp tKO mice: ~15% GFP+ penetrated the DREZ and remained within ~200µm
1032 of the border. ChABC-expressed tKO vs. WT: 100µm, **p=0.0022, df=186; 200µm,
1033 ***p=0.0003, df=186; 300µm, p=0.4818, df=186. ChABC-expressed tKO vs. tKO: 100µm,
1034 **p=0.0086, df=186; 200µm, **p=0.0099, df=186; 300µm, p=0.9262, df=186. Two-way
1035 repeated-measures ANOVA with Sidak's multiple comparisons test (WT: 13 sections, 3 mice;
1036 tKO: 16 sections, 5 mice; ChABC-tKO: 14 sections, 3 mice). S.C., spinal cord; ns, not
1037 significant. Scale bars=200µm **(B, C, C')**.

1038
1039 **Figure 5. Chronic regeneration failure at the DREZ lacking Nogo/MAG/OMgp and CSPGs**
1040 DR regeneration in WT **(A-D)**, Nogo/MAG/OMgp tKO **(E-G)**, and ChABC-expressed
1041 Nogo/MAG/OMgp tKO mice **(H-K)** analyzed 4 weeks after L4 and L5 DR crush. **(A)** Schematic
1042 illustration of the experimental procedures. **(B)** Wholemout view of L5 DREZ in a WT mouse
1043 showing no noticeably enhanced regeneration into the spinal cord. **(C, C')** Transverse sections
1044 showing no improved penetration of GFP+ (green) and CGRP+ axons (magenta) through the
1045 DREZ. **(D)** Quantitative comparisons of WT mice at 2wpi and 4wpi illustrating no significant
1046 difference. 100µm, p=0.5292, df=102. Two-way repeated-measured ANOVA with Sidak's
1047 multiple comparisons test (WT-2wpi: 13 sections, 3 mice; WT-4wpi: 14 sections, 4 mice). **(E)**
1048 Wholemout view of L4-L5 DREZ in a tKO showing no marked increase in intraspinal
1049 regeneration. **(F, F')** Transverse sections of a tKO mouse showing GFP+ (green) and CGRP+
1050 axons (magenta) remaining at the DREZ at 4 wpi. **(G)** Quantitative comparisons of tKO mice at
1051 2wpi and 4wpi illustrating no significant difference. 100µm, p=0.5067, df=168; 200µm,
1052 p>0.9999, df=168; 300µm, p>0.9999, df=168. Two-way repeated-measures ANOVA with

1053 Sidak's multiple comparisons test (tKO-2wpi: 16 sections, 5 mice; tKO-4wpi: 14 sections, 5
1054 mice). **(H)** Wholemout view of L4-L5 DREZ in a ChABC-expressed tKO showing no
1055 noticeably enhanced intraspinal regeneration. **(I, I')** Transverse sections of a ChABC-expressed
1056 tKO showing GFP+ (green) and CGRP+ axons (magenta) remaining at the DREZ at 4wpi. **(J)**
1057 Quantitative comparisons of ChABC-expressed tKO mice at 2wpi and 4wpi illustrating no
1058 significant increase in GFP+ axons that penetrated the DREZ. 100 μ m, $p=0.0027$, $df=60$; 200 μ m,
1059 $p=0.936$, $df=60$; 300 μ m, $p>0.9999$, $df=60$. Two-way repeated-measures ANOVA with Sidak's
1060 multiple comparisons test (ChABC-tKO-2wpi: 14 sections, 3 mice; ChABC-tKO-4wpi: 12
1061 sections, 3 mice). **(K)** Quantitative comparisons of WT, tKO and ChABC-expressed tKO at 4wpi
1062 showing no significant difference in GFP+ axons crossing the DREZ. ChABC-expressed tKO vs.
1063 WT: 100 μ m, $***p=0.0001$, $df=144$; 200 μ m, $p=0.668$, $df=144$; 300 μ m, $p=0.7582$, $df=144$). Two-
1064 way repeated-measures ANOVA with Sidak's multiple comparisons test. Scale bars=200 μ m **(B,**
1065 **C-C', E-F', H-I')**.

1066

1067 **Figure 6. Conditioned DR axons do not penetrate the DREZ lacking Nogo/MAG/OMgp**

1068 **(A)** Schematic illustration of the experimental procedures. Nogo/MAG/OMgp tKO mice
1069 received a nerve conditioning lesion 10 days before L4 and L5 DR crush and were assessed at
1070 2wpi. **(B)** Wholemout view of a conditioned tKO showing hundreds of GFP+ axons terminated
1071 near the astrocyte:PNS border (dotted line), as in WT and tKO mice. **(C, C')** Transverse sections
1072 of a conditioned tKO illustrating little if any enhanced regeneration of GFP+ (green) or CGRP+
1073 axons (magenta) across the DREZ. An arrow denotes occasionally observed GFP+ axons that
1074 reached dorsolateral grey matter. **(D)** Quantitative comparisons illustrating no significant
1075 difference in WT, tKO and conditioned tKO mice. tKO vs. conditioned tKO: 100 μ m, $****p <$
1076 0.0001 , $df=220$; 200 μ m, $p = 0.9991$, $df=220$; 300 μ m, $p > 0.9999$, $df=220$. Two-way repeated-
1077 measures ANOVA with Sidak's multiple comparisons test (WT: 13 sections, 3 mice; tKO: 16
1078 sections, 5 mice; conditioned-tKO: 11 sections, 3 mice). ns, not significant. Scale bars=200 μ m
1079 **(B, C, C')**.

1080

1081 **Figure 7. Additional CSPG removal does not enhance penetration in conditioned tKO mice**

1082 **(A)** Schematic illustration of the experimental procedures. LV-ChABC was injected into
1083 Nogo/MAG/OMgp tKO mice that received a conditioning lesion 10 days before L4 and L5 DR

1084 crush. **(B)** Wholemout view of a ChABC/conditioned tKO showing hundreds of GFP+ axons
1085 that remain near the border (dotted line). **(C-C')** Transverse sections of a ChABC/conditioned
1086 tKO illustrating effective CSPG degradation confirmed by the lack of CS-56 immunoreactivity
1087 (asterisks) and little if any intraspinal regeneration of GFP+ axons. **(D-D')** Additional transverse
1088 sections of a ChABC/conditioned tKO illustrating limited intraspinal regeneration of GFP+ or
1089 CGRP+ axons (magenta). Arrows denote occasionally observed GFP+ axons that enter dorsal
1090 grey matter. **(E)** Quantitative comparisons illustrating no significant difference in
1091 ChABC/conditioned tKO and conditioned tKO mice. 100 μ m, $p=0.7629$, $df=114$; 200 μ m, $p=0.$
1092 2671, $df=114$. Two-way repeated-measures ANOVA with Sidak's multiple comparisons test
1093 (conditioned tKO: 11 sections, 3 mice; ChABC/conditioned tKO: 10 sections, 4 mice). **(F)**
1094 Quantitative summary illustrating minimal intraspinal regeneration of even conditioned axons
1095 after concurrent removal of myelin inhibitors and CSPGs; Only ~10% GFP+ axons extended
1096 ~100 μ m past the DREZ. 100 μ m, $*p=0.0488$, $df=300$ (WT vs ChABC expressed tKO),
1097 $****p<0.0001$, $df=300$ (WT vs conditioned tKO, WT vs ChABC/conditioned tKO); 200 μ m,
1098 $*p=0.014$, $df=300$ (WT vs ChABC expressed tKO, $**p=0.0024$, $df=300$ (WT vs
1099 ChABC/conditioned tKO); 300 μ m, $p>0.9999$; $df=300$. Two-way repeated-measures ANOVA
1100 with Sidak's multiple comparisons test. Scale bars=200 μ m (**B, C, C', D, D'**).

1101

1102 **Figure 8. Nogo/MAG/OMgp removal markedly enhances GDNF-induced intraspinal**
1103 **regeneration**

1104 GDNF-induced intraspinal regeneration analyzed in WT (**A-D**) and Nogo/MAG/OMgp tKO
1105 mice (**E-G'**) 2 weeks after L4 and L5 DR crush. **(A)** Schematic illustration showing intraspinal
1106 injections of LV-GDNF at the time of root crush and AAV2-GFP injections in WT mice. **(B)**
1107 Wholemout view of a GDNF-expressed WT illustrating hundreds of GFP+ axons largely
1108 remaining near the border. **(C-C')** Transverse sections of a GDNF-expressed WT showing a
1109 number of GFP+ (green) or CGRP+ axons (magenta) that cross the DREZ and extend further
1110 into the dorsal funiculus and grey matter. **(D)** Quantitative comparisons illustrating significantly
1111 enhanced penetration of GFP+ axons across the DREZ. 100 μ m, 200 μ m and 300 μ m,
1112 $****p<0.0001$, $df=156$; 400 μ m, $p=0.2446$, $df=156$. Two-way repeated-measures ANOVA with
1113 Sidak's multiple comparisons test (WT: 13 sections, 3 mice; GDNF-expressed WT: 15 sections,
1114 3 mice). **(E)** Schematic illustration of the experimental procedures in Nogo/MAG/OMgp tKO

1115 mice. **(F)** Wholemout view of a GDNF-expressed tKO mouse revealing intensely fluorescent
1116 area of the L4 and L5 DREZ (arrows), likely due to densely accumulated subdural GFP+ axons.
1117 **(G-G')** Transverse sections of a GDNF-expressed tKO mouse displaying numerous GFP+ axons
1118 regenerating deep into dorsal horn. Asterisks denote CGRP immunoreactivity in deep dorsal
1119 laminae (magenta), presumably indicating enhanced regeneration of CGRP+ axons in GDNF-
1120 expressed tKO, as compared to that in GDNF-expressed WT. **(H)** Quantitative comparisons
1121 illustrating markedly greater intraspinal growth of GFAP-labeled axons in GDNF-expressed tKO
1122 than in GDNF-expressed WT mice. 100 μ m and 200 μ m, **** p <0.0001, df =174; 300 μ m,
1123 * p =0.028, df =174; 400 μ m, p =0.9975, df =174. Two-way repeated-measures ANOVA with
1124 Sidak's multiple comparisons test (GDNF-expressed WT: 15 sections, 3 mice; GDNF-expressed
1125 tKO: 16 sections, 5 mice). ns, not significant. Scale bars=200 μ m (**B, C, C', F, G, G'**).

1126

1127 **Figure 9. CSPG removal further enhances GDNF-induced intraspinal regeneration in**
1128 **Nogo/MAG/OMgp tKO mice**

1129 **(A)** Schematic illustration of the experimental procedures. LV-ChABC and LV-GDNF were
1130 injected into dorsal horn along the L4-L5 DREZ in Nogo/MAG/OMgp tKO mice. **(B)**
1131 Wholemout view of a ChABC/GDNF-expressed tKO showing broader areas of the DREZ and
1132 the CNS with densely accumulated GFP+ axons (arrows). Arrowheads denote numerous axons
1133 extending rostrocaudally close to the midline. **(C-C')** Transverse sections of a ChABC/GDNF-
1134 expressed tKO showing effective degradation of CSPGs confirmed by CS-56 immunoreactivity
1135 and many GFP+ axons densely filling broad and deep areas of the dorsal horn. **(D)** Transverse
1136 sections of a ChABC/GDNF-expressed tKO showing enhanced intraspinal regeneration of GFP+
1137 axons and CGRP+ axons (magenta). CGRP+ immunoreactivity is bright, dense and remarkably
1138 restricted to the superficial laminae. **(E)** Quantitative comparisons illustrating significantly more
1139 GFP+ axons in deeper portions of the dorsal horn in ChABC/GDNF-expressed tKO. 100 μ m,
1140 p =0.5389, df =210; 200 μ m, p =0.9891, df =210; 300 μ m, p =0.2358, df =210; 400 μ m, p =0.0074,
1141 df =210; 500 μ m, p =0.5805, df =210. Two-way repeated-measures ANOVA with Sidak's multiple
1142 comparisons test (ChABC/GDNF-expressed tKO: 19 sections, 8 mice; GDNF-expressed tKO: 16
1143 sections, 5 mice). ns, not significant. Scale bars=200 μ m (**B, C, C', D**).

1144




Figure 1. Intraganglionic AAV2-GFP labels proprioceptive and mechanoreceptive axons

(A) Schematic illustration of intraganglionic injection of scAAV2-eGFP and a representative DRG showing infected neurons expressing GFP at 2 weeks post-injection. (B) Mice expressing GFP in >70% Nissl-stained neurons were used in the present study. (C) DRG transverse sections showing GFP+ neurons (arrows) co-expressing neurofilament (NF), IB4, or CGRP. (D) Quantitative comparisons of AAV2-GFP infected neurons illustrating preferential labeling of large-diameter myelinated NF+ neurons, which mediate proprioception and mechanoreception. n>20 sections, 3 mice. (E) A transverse section showing GFP+ axons along the root and within the right side of the spinal cord, projecting into dorsal column, deeper laminae of the dorsal horn and into the ventral horn. An arrow denotes superficial laminae I-III lacking GFP fluorescence. (E', E'') Enlarged views of the superficial dorsal horn, illustrating lack of GFP-fluorescence where CGRP+ nociceptive axons (magenta) innervate. DH, dorsal horn; DR, dorsal root; VH; ventral horn. Scale bars=50µm (A, C, E', E''), 200µm (E).






Figure 2. Additional strategies for complete lesions and evaluation of DR regeneration

DR regeneration in adult wildtype mice assessed in wholemounts (A-D) and transverse sections (E, F) 2 weeks after L4 and L5 DR crush. (A) Schematic illustration of crushing roots prior to intraganglionic AAV2-GFP injections to avoid labeling of degenerating distal stump axons. (B) Wholemount view of completely crushed L4 and L5 DRs illustrating hundreds of GFP+ axons terminated at the entrance of spinal cord. (B', B'') Enlarged views illustrating most axons terminated near the border. (C-C'') Wholemount views of incompletely crushed DRs showing spared axons with long intraspinal projections. Spared axons are easily detectable in wholemounts and commonly observed in the outermost dorsal rootlets (arrows). (D) Wholemount view of L4 DREZ illustrating GFP+ axons that crossed the astrocyte:PNS border (dotted line) and terminated nearby. The astrocytic border is identified by GFAP immunostaining of astrocytes (red). Yellow line denotes spinal cord midline recognized by the midline vein. (E) Four-color immunolabeling of transverse sections illustrating limited penetration of GFP+ or CGRP+ axons through the DREZ. White dotted lines


A




D



B



C



C'




Figure 4. Additional CSPG removal enables minimal intraspinal regeneration in tKO myelin mutants

DR regeneration in ChABC-expressed Nogo/MAG/OMgp tKO mice assessed in wholemounts (B) and transverse sections (D, C) 2 weeks after L4 and L5 DR crush. (A) Schematic illustration of the experimental procedures. LV-ChABC was injected into ipsilateral dorsal horn at multiple locations rostrocaudally along the L4-L5 DREZ. (B) Wholemount views of a ChABC-expressed tKO showing hundreds of GFP+ axons in L4 and L5 roots terminated near the astrocyte:PNS border (dotted line), as in WT and tKO mice. The astrocytic border is identified by GFAP immunostaining of astrocytes (red). (C) Representative transverse sections illustrating effective degradation of CSPGs and modestly enhanced intraspinal regeneration. CS-56 immunoreactivity is very low in ipsilateral dorsal horn (asterisks), indicating effective removal of inhibitory GAG chains of CSPGs. Arrowheads denote Schwann cell-associated CS-56 immunoreactivity, which is markedly reduced but discernable in ChABC-expressed tKO. (C') Enlarged views showing a few GFP+ axons that penetrated the DREZ and are located at the top of the dorsal horn (arrows); such axons were not observed in WT or Nogo/MAG/OMgp tKO mice. (D) Quantitative comparisons illustrating modestly improved regeneration in ChABC-expressed Nogo/MAG/OMgp tKO mice: ~15% GFP+ penetrated the DREZ and remained within ~200µm of the border. ChABC-expressed tKO vs. WT: 100µm, **p=0.0022, df=186; 200µm, ***p=0.0003, df=186; 300µm, p=0.4818, df=186. ChABC-expressed tKO vs. tKO: 100µm, **p=0.0086, df=186; 200µm, **p=0.0099, df=186; 300µm, p=0.9262, df=186. Two-way repeated-measures ANOVA with Sidak's multiple comparisons test (WT: 13 sections, 3 mice; tKO: 16 sections, 5 mice; ChABC-tKO: 14 sections, 3 mice). S.C., spinal cord; ns, not significant. Scale bars=200µm (B, C, C').




Figure 5. Chronic regeneration failure at the DREZ lacking Nogo/MAG/OMgp and CSPGs

DR regeneration in WT (A-D), Nogo/MAG/OMgp tKO (E-G), and ChABC-expressed Nogo/MAG/OMgp tKO mice (H-K) analyzed 4 weeks after L4 and L5 DR crush. (A) Schematic illustration of the experimental procedures. (B) Wholemount view of L5 DREZ in a WT mouse showing no noticeably enhanced regeneration into the spinal cord. (C, C') Transverse sections showing no improved penetration of GFP+ (green) and CGRP+ axons (magenta) through the DREZ. (D) Quantitative comparisons of WT mice at 2wpi and 4wpi illustrating no significant difference. 100 μ m, $p=0.5292$, $df=102$. Two-way repeated-measured ANOVA with Sidak's multiple comparisons test (WT-2wpi: 13 sections, 3 mice; WT-4wpi: 14 sections, 4 mice). (E) Wholemount view of L4-L5 DREZ in a tKO showing no marked increase in intraspinal regeneration. (F, F') Transverse sections of a tKO mouse showing GFP+ (green) and CGRP+ axons (magenta) remaining at the DREZ at 4 wpi. (G) Quantitative comparisons of tKO mice at 2wpi and 4wpi illustrating no significant difference. 100 μ m, $p=0.5067$, $df=168$; 200 μ m, $p>0.9999$, $df=168$; 300 μ m, $p>0.9999$, $df=168$. Two-way repeated-measures ANOVA with Sidak's multiple comparisons test (tKO-2wpi: 16 sections, 5 mice; tKO-4wpi: 14 sections, 5 mice). (H) Wholemount view of L4-L5 DREZ in a ChABC-expressed tKO showing no noticeably enhanced intraspinal regeneration. (I, I') Transverse sections of a ChABC-expressed tKO showing GFP+ (green) and CGRP+ axons (magenta) remaining at the DREZ at 4wpi. (J) Quantitative comparisons of ChABC-expressed tKO mice at 2wpi and 4wpi illustrating no significant increase in GFP+ axons that penetrated the DREZ. 100 μ m, $p=0.0027$, $df=60$; 200 μ m, $p=0.936$, $df=60$; 300 μ m, $p>0.9999$, $df=60$. Two-way repeated-measures ANOVA with Sidak's multiple comparisons test (ChABC-tKO-2wpi: 14 sections, 3 mice; ChABC-tKO-4wpi: 12 sections, 3 mice). (K) Quantitative comparisons of WT, tKO and ChABC-expressed tKO at 4wpi showing no significant difference in GFP+ axons crossing the DREZ. ChABC-expressed tKO vs. WT: 100 μ m, $***p=0.0001$, $df=144$; 200 μ m, $p=0.668$, $df=144$; 300 μ m, $p=0.7582$, $df=144$). Two-way repeated-measures ANOVA with Sidak's multiple comparisons test. Scale bars=200 μ m (B, C-C', E-F', H-I').




Figure 6. Conditioned DR axons do not penetrate the DREZ lacking Nogo/MAG/OMgp

(A) Schematic illustration of the experimental procedures. Nogo/MAG/OMgp tKO mice received a nerve conditioning lesion 10 days before L4 and L5 DR crush and were assessed at 2wpi. (B) Wholemount view of a conditioned tKO showing hundreds of GFP+ axons terminated near the astrocyte:PNS border (dotted line), as in WT and tKO mice. (C, C') Transverse sections of a conditioned tKO illustrating little if any enhanced regeneration of GFP+ (green) or CGRP+ axons (magenta) across the DREZ. An arrow denotes occasionally observed GFP+ axons that reached dorsolateral grey matter. (D) Quantitative comparisons illustrating no significant difference in WT, tKO and conditioned tKO mice. tKO vs. conditioned tKO: 100 μ m, **** $p < 0.0001$, $df=220$; 200 μ m, $p = 0.9991$, $df=220$; 300 μ m, $p > 0.9999$, $df=220$. Two-way repeated-measures ANOVA with Sidak's multiple comparisons test (WT: 13 sections, 3 mice; tKO: 16 sections, 5 mice; conditioned-tKO: 11 sections, 3 mice). ns, not significant. Scale bars=200 μ m (B, C, C').





Figure 7. Additional CSPG removal does not enhance penetration in conditioned tKO mice

(A) Schematic illustration of the experimental procedures. LV-ChABC was injected into Nogo/MAG/OMgp tKO mice that received a conditioning lesion 10 days before L4 and L5 DR crush. **(B)** Wholemount view of a ChABC/conditioned tKO showing hundreds of GFP+ axons that remain near the border (dotted line). **(C-C')** Transverse sections of a ChABC/conditioned tKO illustrating effective CSPG degradation confirmed by the lack of CS-56 immunoreactivity (asterisks) and little if any intraspinal regeneration of GFP+ axons. **(D-D')** Additional transverse sections of a ChABC/conditioned tKO illustrating limited intraspinal regeneration of GFP+ or CGRP+ axons (magenta). Arrows denote occasionally observed GFP+ axons that enter dorsal grey matter. **(E)** Quantitative comparisons illustrating no significant difference in ChABC/conditioned tKO and conditioned tKO mice. 100 μ m, $p=0.7629$, $df=114$; 200 μ m, $p=0.2671$, $df=114$. Two-way repeated-measures ANOVA with Sidak's multiple comparisons test (conditioned tKO: 11 sections, 3 mice; ChABC/conditioned tKO: 10 sections, 4 mice). **(F)** Quantitative summary illustrating minimal intraspinal regeneration of even conditioned axons after concurrent removal of myelin inhibitors and CSPGs; Only ~10% GFP+ axons extended ~100 μ m past the DREZ. 100 μ m, $*p=0.0488$, $df=300$ (WT vs ChABC expressed tKO), $****p<0.0001$, $df=300$ (WT vs conditioned tKO, WT vs ChABC/conditioned tKO); 200 μ m, $*p=0.014$, $df=300$ (WT vs ChABC expressed tKO, $**p=0.0024$, $df=300$ (WT vs ChABC/conditioned tKO); 300 μ m, $p>0.9999$; $df=300$. Two-way repeated-measures ANOVA with Sidak's multiple comparisons test. Scale bars=200 μ m (**B**, **C**, **C'**, **D**, **D'**).






Figure 9. CSPG removal further enhances GDNF-induced intraspinal regeneration in Nogo/MAG/OMgp tKO mice

(A) Schematic illustration of the experimental procedures. LV-ChABC and LV-GDNF were injected into dorsal horn along the L4-L5 DREZ in Nogo/MAG/OMgp tKO mice. (B) Wholemout view of a ChABC/GDNF-expressed tKO showing broader areas of the DREZ and the CNS with densely accumulated GFP+ axons (arrows). Arrowheads denote numerous axons extending rostrocaudally close to the midline. (C-C') Transverse sections of a ChABC/GDNF-expressed tKO showing effective degradation of CSPGs confirmed by CS-56 immunoreactivity and many GFP+ axons densely filling broad and deep areas of the dorsal horn. (D) Transverse sections of a ChABC/GDNF-expressed tKO showing enhanced intraspinal regeneration of GFP+ axons and CGRP+ axons (magenta). CGRP+ immunoreactivity is bright, dense and remarkably restricted to the superficial laminae. (E) Quantitative comparisons illustrating significantly more GFP+ axons in deeper portions of the dorsal horn in ChABC/GDNF-expressed tKO. 100μm, $p=0.5389$, $df=210$; 200μm, $p=0.9891$, $df=210$; 300μm, $p=0.2358$, $df=210$; 400μm, $p=0.0074$, $df=210$; 500μm, $p=0.5805$, $df=210$. Two-way repeated-measures ANOVA with Sidak's multiple comparisons test (ChABC/GDNF-expressed tKO: 19 sections, 8 mice; GDNF-expressed tKO: 16 sections, 5 mice). ns, not significant. Scale bars=200μm (B, C, C', D).